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The number of diabetes cases are on the rise worldwide. To address 
this issue, various high-throughput screening (HTS) assays (e.g. p-
nitrophenyl-α-D-glucopyranoside (pNPG) and glucose oxidase/peroxidase 
(GOP) assays) have been applied but not properly evaluated in their 
application to the screening of starch hydrolase inhibitors in botanicals.  
The pNPG assay uses a synthetic substrate, contrary to the GOP assay, 
which applies the natural substrate maltose. The impact of substrates on 
inhibitor potency was assessed by determining the Ki and Ki′ of acarbose and 
1-Deoxynojirimycin (1-DNJ). Application of pNPG resulted in consistently 
higher Ki for both inhibitors compared to maltose. Larger Ki translates to 
larger IC50 (i.e. lower potency). The mode of inhibition, however, remained 
the same despite the change in substrate. The importance of applying natural 
substrates is warranted in order for the results to be representative and 
applicable.  
The GOP assay was developed initially to quantitate the amount of D-
glucose in human fluids but its application has since been expanded to screen 
for starch hydrolase inhibitors in botanicals. It was illustrated that the majority 
of polyphenolic compounds found within the plant kingdom caused significant 
interference to the GOP assay, which makes it not useful in measuring the α-
glucosidase inhibition activity of botanical extracts. More specifically, 
compounds which possess many hydroxyl groups, particularly in the ortho 
position of the B-ring in flavonoids, tend to produce higher interference. 
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Medicinal plants are biochemically diverse and provide an important 
resource for plant-based medicinal therapy. However, an estimation of less 
than 10 % of these plant species has been investigated chemically. As such, 
the WHO recommended (in a 1991 report on diabetes) that intensive research 
on the beneficial effects of medicinal plants be performed. In line with this, 
collaborative work with the Singapore Botanic Gardens (healing garden) was 
carried out to screen a total of 298 medicinal plants for α-amylase and α-
glucosidase inhibition activity. This screening lays the groundwork for future 
in-depth studies of isolation and characterization of inhibitors. A further step 
was taken to apply assay-guided fractionation and separation of polyphenolic 
compounds from the ginger flower (Etlingera elatior). Results indicate that 
potent α-amylase inhibitory activity of E. elatior extract was largely attributed 
to the presence of proanthocyanidins (PAC). It is possible that other inhibitors 
besides PAC are present in the aqueous phase.  
Finally, a study was done on the synergistic effects of epigallocatechin 
gallate (EGCG) with acarbose and dracoflavan B (DFB) with the rationale of 
enhancing the effectiveness of conventional drugs through the use of 
commonly consumed foods like tea. Acarbose and DFB was shown to be able 
to work together synergistically with EGCG to inhibit α-amylase through 
“bliss independence” mechanism. The extent of synergy is dependent on the 
amount of EGCG in the system. This study provides new insight into the use 
of naturally occurring enzyme inhibitors in foods rich in EGCG (eg. green tea) 
as a supplement to aid in the treatment of diabetes. 
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Diabetes is a progressive metabolic disorder of multiple etiologies 
characterized by an increase in blood glucose level, due to the disruption of 
the homeostasis of carbohydrate metabolism that results from defects in 
insulin secretion, insulin action, or both (1). The majority of diabetes cases fall 
into either of two broad etiopathogenetic categories: type I or type II diabetes 
(T2D). In type I diabetes, the patient has an absolute deficiency of insulin 
secretion, which is due primarily to the destruction of pancreatic islet β-cells, 
which are needed to produce insulin. This type of diabetes is linked to an 
autoimmune pathological process that occurs in the pancreatic islets and by 
genetic markers (2). In the other category, T2D, also being much more 
prevalent, is caused by a combination of insulin resistance as well as an 
inadequate compensatory insulin secretory response. Insulin resistance occurs 
when the beta cells are able to produce insulin but the body is unable to use it 
effectively due to a resistance of the body to the action of insulin (2).  
Due to a defect in the production of insulin in diabetic patients, the 
degradation of starch by starch hydrolases proceeds rapidly and leads to 
elevated postprandial hyperglycaemia (PPHG), which is a key risk factor of 
the disease. The high blood glucose level in diabetic patients can lead to 
complications that include coronary heart disease, stroke, peripheral arterial 
disease, nephropathy, retinopathy, and possibly neuropathy and 
3 
 
cardiomyopathy (3). Since an increase in PPHG has been shown to correlate 
with the activity of human pancreatic -amylase (4), the inhibition of 
intestinal -glucosidase can retard the rate of carbohydrate digestion, thereby 
reducing PPHG. This also buys time for the beta cells to secrete more insulin 
and reduce glucose levels in the circulatory system (5).  
The World Health Organization (WHO) suggests that the world is in a 
midst of a diabetes epidemic, and estimated that this disorder affects some 100 
million people worldwide (6, 7). Furthermore, this number is predicted to 
reach 336 million people by year 2030, where people from South East Asia 
and the Western Pacific are considered most at risk (8). A serious and relevant 
problem caused by diabetes is its cost on society, which is estimated to be 5-
10% of national health budgets, and this excludes additional costs of 
cardiovascular diseases, blindness, amputations and kidney failure that can be 
attributed to diabetes (9, 10). In view of this, there is an inherent need for a 
cure or a preventative control for hyperglycaemia, the main concern of 
diabetic patients. Numerous researches has been invested into this area of need 
but despite extensive diabetes research, there is a lack of effective and safe 
means in controlling PPHG through food consumption. An interesting concept 
to explore would be the use of everyday foods to control PPHG. In line with 
this, tea is a suitable candidate to fulfil this role, since, in most cultures, it is 
regularly consumed, and has been linked to health-promoting effects like anti-
diabetes in epidemiological studies (11).  
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1.2 Anti-diabetic effects of tea catechins  
Tea (Camelia sinensis) is believed to be the most widely consumed 
beverage in the world, as it has often been associated with longevity and the 
prevention of many diseases (12-17). Much interest has been generated in its 
potential health benefits, as animal models and in vitro studies have 
demonstrated its anti-oxidant, anti-mutagenic, anti-carcinogenic and anti-
hypertensive properties (18-21). Teas may be largely categorized by its degree 
of fermentation: non-fermented (green tea), semi-fermented (oolong tea) and 
fermented (black tea), each giving very different chemical profiles. For 
example, the chemical composition of green tea is quite complex, comprising 
polysaccharides, polyphenols, amino acids and alkaloids. However, its health 
benefiting properties have been largely attributed to its rich catechin contents, 
which are comprised of (-)-catechin, (-)-epicatechin, (-)-gallocatechin, (-)-
epicatechin gallate, (-)-epigallocatechin, (-)-gallocatechin and (-)-
epigallocatechin gallate (EGCG) (Figure 1). Among these catechins, EGCG is 
most abundant in green tea, and is thought to be a major contributor to the 
health benefits ascribed to tea.   
 
Contrary to the findings of the potential health-benefiting properties of 
tea in human clinical trials, epidemiological studies on the effects of tea 
consumption on cancer and cardiovascular diseases have not been consistent 
(22). Nonetheless, epidemiological studies are complex and the 
inconsistencies among them could be attributed to many factors such as 






Figure 1. Chemical structures of green tea flavan-3-ols (Adapted from Stalmach et. 
al. 2009) (23).  
 
In addition, it is also possible that these inconsistencies stem from the 
fact that the actual mechanisms of the anti-diabetic properties of tea could be 
highly complex, and due to potential multiple-action pathways and roles of 
different constituents in tea. Taking EGCG as an example, various studies 
showed the anti-diabetic effects of EGCG alone influences cellular 
interactions via different pathways and some of the proposed mechanisms are 
listed below and summarized in Figure 2.  
a. Lowering appetite 
An in vivo study demonstrated that when EGCG was injected into the 
intraperitoneum of mice, it resulted in a decrease in food intake, which may be 
related to changes in its appetite (24). 
b. Increasing protection of diabetes-related cells 
Due to its high antioxidant activity, EGCG is able to alter the redox 
status in many cells, and thus, give a protective effect on these cells (e.g. liver, 
β-pancreatic, nerve cells) from oxidative stress. For example, in vitro EGCG 
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treatment was shown to reduce the production of destructive nitric oxide, 
which in turn protects against interleukin-1 β and interferon  cytotoxicity in 
RINm5F insulinoma cells (a pancreatic β-cell) (25). 
c. Enhancing insulin sensitivity / Increasing insulin-like activity 
In vitro, EGCG enhanced insulin sensitivity by inducing a greater 
insulin activity, 17-fold, using epididymal fat cell assay compared to the 
control (26). This was consistent with in vivo studies where 0.5 g of 
lyophilized green tea powder dissolved in 100 mL of deionized distilled water 
was able to stimulate insulin (1 nM)-induced glucose uptake by rat adipocytes 
(27, 28). 
d. Enzyme inhibition 
Green tea catechins have been shown to regulate the activity and/or 
expression of enzymes and proteins that are related to carbohydrate digestion, 
absorption, transport, synthesis and metabolism. For example, during dietary 
starch and sucrose digestion, tea catechins can inhibit intestinal glucose 
transporter type 2 and sodium-dependent glucose transporter (SGLT1), which 
is responsible for glucose uptake into cells (29). In addition, many in vitro 
studies have also demonstrated that tea catechins are able to inhibit starch 
hydrolases like α-amylase and α-glucosidase, which reduces the breakdown of 
complex carbohydrates to simple sugars and lengthens the digestion process, 
thereby modulating blood glucose levels (30-34). It is likely that the prime 
target of tea polyphenols (for its effects on glucose metabolism) is via this 
mechanism, since the gut lumen has the highest concentration of polyphenols, 




Figure 2. Proposed mechanisms of action of EGCG on diabetes prevention (Adapted 
from Kao et. al. 2006) (36). 
 
1.3 Enzyme inhibition as a means for prevention of post-prandial 
hyperglycaemia. 
In the digestive system, pancreatic enzymes like -amylase and -
glucosidase are responsible for hydrolysing starch to maltose and finally to 
glucose.  
Flavan-3-ols present in foods that are consumed pass through the oral 
cavity and are able to interact with salivary proteins that are rich in proline, 
forming polyphenol-protein complexes through hydrogen and hydrophobic 
interactions (37). However, due to the small amount of protein present within 
the oral cavity, the aggregates formed are not significant enough to alter the 
availabilities of polyphenolic compounds elsewhere in the body (38). In the 
stomach, polyphenolic compounds are then subjected to strong acidic 
conditions, which may influence its structural stability. Nonetheless, 
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experiments on catechins revealed that despite such a harsh acidic 
environment in the stomach, they are still stable (39). In the small intestine, 
flavan-3-ols are hydrolyzed by two active enzymes: lactase-phlorizin 
hydrolase and cytosolic β-glucosidase, which causes the sugar unit to be 
released and an aglycone formed. The lipophilicity of the released aglycone is 
able to enter epithelial cells via passive diffusion and polar glycosides are 
transferred into enterocytes via an active SGLT1 (40). Besides glycosylation, 
polyphenols also undergo glucuronidation and methylation, which is mediated 
by enzymes belonging to the uridine diphosphate glucutonosyltransferase and 
catechol-O-methyltransferases respectively (41, 42). The body transfers the 
polyphenolic compounds via the portal vein to the liver where main coupling 
reactions like sulfation, methylation and glucuronidation takes place. These 
coupling reactions facilitate their elimination in the bile and urine by increased 
solubility of the metabolites. In addition, phenolic compounds may also 
undergo oxidation, reduction, hydrolysis and hydration reactions which are 
catalyzed by phase 1 enzymes (43).  
Despite the biochemical reactions that take place in the prior sections, 
the main site for polyphenol absorption occurs in the large intestine, where 
colonic microflora play a major role in the catabolism of these compounds. It 
was found that polyphenol concentrations in the gastrointestinal tract exceeded 
1 mM (and possibly even higher) if the compounds are being administered in 
polymeric capsules that can be hydrolyzed by bacterial glycosidases (44, 45).  
Hence, this highlights the importance of starch hydrolase inhibitors as 
a promising and potential solution to the prevention of hyperglycaemia since 
polyphenolic compounds are largely present within the gastrointestinal tract 
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where main starch hydrolases are present. Furthermore, this mechanism does 
not require the active compounds to be absorbed into the blood stream and 
pass through modifications by liver enzymes (46). In fact, some existing 
conventional pharmacological treatments for the control of T2D (like acarbose) 
act through this mode of action, but they are not without their limitations. 
Acarbose, a known α-glucosidase inhibitor, produces undesirable 
gastrointestinal side effects like diarrhoea, flatulence and abdominal pain 
when ingested, making it unpopular as an anti-diabetic drug (47).  
The reason behind these side effects was suggested to be because of 
their non-specificity in targeting different glycosidases, resulting in abnormal 
bacterial fermentation of undigested carbohydrates in the colon (48). 
Therefore, this opens up a need to discover more specific and effective 
enzyme inhibitors, which continues to be an important area of investigation. 
Those inhibitors that can be found in foods (such as fruits and vegetables) and 
botanicals are of particular interest, because they are non-toxic and suitable for 
application as ingredients in starchy foods, having less regulatory concerns. It 
would be ideal to control hyperglycaemia through the development of 
functional foods or beverages that can slow down the speed of carbohydrate 
digestion and absorption.   
1.4 High-throughput screening (HTS), a strategy to identify enzyme 
inhibitors 
In the quest to identify promising leads on starch hydrolase inhibitors 
derived from natural sources, the use of HTS methods are typically applied. 
HTS has become an important and integral strategy in the path of drug 
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discovery. Some of the factors which contribute to good HTS methods are: 
automation, cost-effectiveness, and the use of substrates and enzymes that are 
physiologically relevant. Firstly, automation is important because it provides 
speed, repeatability and robustness. Secondly, the consideration of cost is 
vital, as the quantity of runs is expected to be high, in order to be able to find a 
good lead. Finally, the substrates and enzymes utilized in the assay should be 
natural and physiologically representative, and they should not interfere with 
the signal or response. Furthermore, it is vital that these assays would be 
validated and optimized so that it maintains fidelity to the chemical 
interactions occurring in the human body.  
Within the literature, the reported inhibition potencies (i.e. IC50) of 
pure compounds (e.g. EGCG and acarbose) against starch hydrolases were 
extremely scattered amongst different research groups (Appendix 1). This 
may have been attributed in part to the choice of enzymes used from different 
origins. For instance, α-glucosidases have been isolated and purified from a 
variety of sources ranging from plants (49), bacteria (50), yeast (51), fungi 
(52) to animal origins (53). On the basis of the differences which exist in its 
primary structure, α-glucosidase may be largely divided into types I (e.g. 
baker‟s yeast) and II (e.g. mammals).   
Acarbose, a frequently used positive control in inhibition studies, was 
shown to have varying IC50 values between different studies, which may be 
linked to the type of enzymes used. For example, several studies from 
different research groups utilized the 4-nitrophenyl α-D-glucopyranoside 
(pNPG) assay with yeast α-glucosidase (54-57), and their results gave IC50 
values that were in the same order of magnitude, but varied significantly at 
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141, 242, 217, and 907.5 µM respectively. There was an exception, however: 
Choi et. al. 2010 (58) utilized the same pNPG assay with yeast α-glucosidase 
as its enzyme source, but their results gave a very deviant IC50 value (9110 
µM) as compared to the other four studies.  
In contrast, when rat intestinal α-glucosidase was used in the pNPG 
assay, it was observed that the IC50 of acarbose was lower by one or two 
orders of magnitude as compared to the IC50 values of pNPG assays with yeast 
α-glucosidase. For example, researches (59, 60) that utilized rat intestinal α-
glucosidase in the pNPG assay reported lower IC50 values (0.18 and 63 µM, 
respectively). The use of bacterial (61), pig and rabbit (60) intestinal α-
glucosidase also gave lower IC50 values of 3.25, 87 and 62 µM respectively, as 
compared to that of yeast α-glucosidase. Similarly, it was also shown that the 
inhibitory effect of various inhibitors against α-glucosidases from different 
origins gave varied results. For example, acarbose was shown to strongly 
inhibit mammalian α-glucosidases but no inhibition was observed in yeast α-
glucosidases (60). 
From these results, it is shown that the magnitude of α-glucosidase 
inhibition is greatly affected by its origin and that the selection of enzymes 
utilized is vital. It is thus essential to use α-glucosidases of animal origin, since 
it mirrors more closely the enzymes found in humans (60).  
1.5 Structural features of human starch hydrolases 
1.5.1 Structure of human maltase-glucoamylase (MGAM) 
The MGAM (EC 3.2.1.20) is an enzyme that is localized in the brush 
border of the small intestine and belongs to glycoside hydrolase family 31. It 
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is composed of peptides with 1857 amino acids (molecular mass 209,702 Da) 
and contains five distinct domains: (a), a small cytosolic domain consisting of 
26 amino acids; (b), a transmembrane domain of about 20 amino acids; (c), o-
glycosylated linker of about 55 amino acids and two homologous catalytic 
domains each consisting of about 900 amino acids. The two catalytic subunits 
comprise an N-terminal subunit that is proximal to the membrane bound end 
and a C-terminal (Figure 3)  (62). 
 
Figure 3. MGAM protein organization (Adapted from Rossi et. al. 2006) (63). 
MGAM is an exoenzyme which catalyzes the release of glucose from 
the reducing ends of starch and hydrolyzes the α-(1, 6) glycosidic linkages 
(64). Its mechanism of bond cleavage is mediated by two catalytic carboxylic 
acid residues, and is proposed to proceed through a positively charged 
oxocarbenium-ion transition-state mechanism. In this mechanism, the function 
of the carboxylate group is proposed to promote the formation of the 
oxacarbenium ion and stabilize intermediates, whereas the carboxyl group 
attaches the oxygen of glucosidic linkage. Hence, they cooperatively undergo 
nucleophilic displacement, of the hydroxyl ion of water to the oxocarbenium 
ion, to finish the reaction (65).  
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There are high similarities between the amino acid sequences within 
MGAM family II and in particular, the catalytic amino acid residues are found 
to be conserved in all MGAMs. For example, some of the sources of MGAM 
family II, like those from human, rabbit and rat intestinal sources, are shown 
to only have regions 2 and 5 in their catalytic sites, with highly similar amino 
acid sequences (in contrast to MGAM family I, which has four conservative 
regions: 1, 2, 3, 4) (64). In addition, MGAM contains a catalytic site made up 
of amino acid sequence tryptophan-X-aspartate-methionine-asparagine-
glutamate (WXDMNE), where X is the variable amino acid, and this sequence 
is found to be similar amongst MGAM family 31, which includes human, 
rabbit, rat, sugar beet, and barley sources (66). 
1.5.2 Structure of α-amylase 
α-amylase (α-1, 4 glucan-4-glucanohydrolase, EC 3.2.1.1) is an 
endoglycosidase and a member of glycosyl-hydrolase family 13, which is 
responsible for catalyzing the hydrolysis of α-(1, 4) glycosidic linkages of 
starch, while bypassing the α-(1-6) linkages of amylopectin components (67). 
Linear maltose oligosaccharides as well as branched isomaltose 
oligosaccharides are generated as a result of the α-amylase hydrolysis of 
starch. There are two types of isoenzymes for porcine pancreatic α-amylases 
(PPA): I and II (68). Although the two isoenzymes have slightly different 
amino acid compositions and isoelectric points, the overall conformations of 
their structural proteins are almost identical (69). X-ray crystallographic 
studies show that the PPA is made up of 496 amino acids on a single 
polypeptide chain. It is composed of three domains: Domain A, the largest 
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catalytic domain with a (β/)8 barrel structure; Domain B, α-helix in structure 
with no definite topology; Domain C, with a Greek key motif (protein 
structure that consists of four adjacent antiparallel strands and their linking 
loops) (70). There are two secondary binding sites (SBS) present on the α-
amylase – the first is located at the interface between domains A and C of the 
free enzyme (70) and the other is located close to the calcium binding site 
(71).  
α-amylases are present in a range of different sources, for example 
fungus, plants and mammals, and there are significant structural differences 
amongst different species (72). On the contrary, the molecular structures of 
mammalian sources (eg. humans and porcines) were shown to be very similar. 
For example, studies on molecular models for the α-amylases from human 
pancreas (73) were described as being highly similar to that of the porcine 
pancreas (74). In addition, a comparison of the pancreatic and salivary α-
amylases of humans and rats revealed that the corresponding cDNA nucleotide 
sequences were highly homologous  (75). 
1.6 Artificial vs. natural substrates 
When measuring the enzyme inhibition activity, the substrates used 
would ideally be native or natural, and be physiologically relevant. Yet, 
artificial substrates are still often used as a substitute for natural ones due to its 
convenience in measuring enzyme kinetics. However, the artificial substrates 
do not always accurately mimic the structure and property of the native 
substrate (such as those found in foods like starch and maltose) and may be a 
contributing factor leading to false conclusions.  
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This is because the structural motif and binding sites, as well as the 
affinity of various substrates to the enzymes, vary considerably from one 
another; in addition, the substrate‟s specificity and susceptibility to inhibitors 
may also vary significantly and therefore affect kinetic parameters like the 
Michaelis constant (Km), catalytic rate of an enzyme (kcat), and inhibitor 
constant (Ki)  (76). For example, the N-terminal of glycoside hydrolase 
maltase-glucoamylase (ntMGAM) was shown to display a clear preference for 





versus 1.4  0.1 s-1mM-1 respectively (77). In addition, it was also 
demonstrated that the use of different substrates (maltose, maltotriose, 
maltotetraose and maltoheptaose) impact the Ki for glucoamylase-maltase with 
1-Deoxynojirimycin (1-DNJ) and acarbose. Their results showed that when 
maltose was used as the substrate, the Ki  values of 1-DNJ (0.76 µM) and of 
acarbose (0.84 µM) were about 100 times higher than the corresponding 
values for hydrolysis as compared to when maltooligosaccharides were used 
(77, 78). 
In addition, the use of synthetic substrates over natural ones would also 
affect the pH optima of the enzymes. A change in pH will most likely affect 
the conformational structure of the enzyme, which will in turn affect the 
binding interaction of ligands (inhibitors or substrates) to the enzyme. It was 
shown that the pH optima of α- and β-amylases was higher with synthetic, as 
opposed to natural, substrates (79).  
In another study, the effect of the nature and concentration of the 
substrate on β-glucosidase activity value was determined. A natural substrate, 
16 
 
cellobiose, and synthetic substrates, salicin and β-nitrophenyl-β-D-glucoside, 
were used to measure β-glucosidase activity. It was found that significant 
variations in values were observed, and it was cautioned that the use of 
synthetic substrates should not be assumed to be representative of an 
organism‟s ability to hydrolyze natural substrates (80). Furthermore, another 
study of enzyme analysis for Pompe disease in leucocytes also noted that the 
use of artificial substrate (4-methylumbelliferyl-α-D-glucoside) is a poor 
alternative to the use of natural substrate (glycogen), as it insufficiently 
distinguishes between affected and unaffected individuals (81). Taken 
together, the evidence demonstrates that the use of most synthetic substrates 
rather than natural ones may generate misleading results, and not be reflective 
of the biochemical reactions occurring in the body. Hence, proper validation 
must be first administered when using synthetic substrates in assays, and the 
results should be interpreted with care. 
1.7 Assays for determining starch hydrolase activity                                                     
1.7.1 Assays to determine α-amylase activity 
One of the popular methods for determining hydrolase activity is based 
on the analysis of reducing sugars formed as a result of glycosidic bond 
cleavage between two carbohydrates, or between a carbohydrate and a non-
carbohydrate moiety. Reducing sugars are sugars with an aldehyde group that 
can act as a reducing agent. Under alkaline conditions, ketoses may behave as 
weak reducing sugars as they are able to isomerise to aldoses. The following 
details several colourimetric methods used to measure reducing sugars. The 
more popular methods are the 3, 5-dinitrosalicylic acid (DNSA) assay and the 
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Nelson-Somogyi assay. The lesser used colourisation reaction is the mixture 
of two reagents, sodium 2, 2‟-bicinchoninate and p-hydroxybenzoic acid 
hydrazide or potassium ferricyanide.  
a. 3,5-Dinitrosalicylic acid assay (82) 
The DNSA assay oxidises reducing sugars with its nitro group, at 
alkaline conditions and high temperatures (100 ºC), to form 3-amino-5-
nitrosalicylic acid, which has a characteristic absorption wavelength at 540 nm 
(Figure 4).  The normal procedure for this assay to test for amylase inhibition 
is to first pre-incubate the inhibitor with the amylase at 37 ºC for 10 minutes. 
Starch (1.0 % w/v) is added to initiate the reaction, and an aliquot of the 
reaction mixture mixed with DNSA reagent and heated to 100 ºC for 5 
minutes, to develop its colour, with the absorbance value read at 540 nm.  
The DNSA assay was initially introduced as a method to detect 
reducing substances in urine and blood (83). Since its inception, the reagent 
has been improved by the addition of Rochelle salt (to reduce dissolved 
oxygen by increasing the ion concentration in the solution), addition of phenol 
(to increase colour intensity) and sodium bisulfite (to react with oxygen 
present and stabilize the reaction colour) (84, 85).  Recently, its application 
has broadened as a screening tool for α-amylase inhibitors. Although a tedious 
method, it is also used as a tool to monitor the kinetics of different modes of 
inhibition (e.g., competitive, non-competitive or uncompetitive inhibition).  
As with most colourimetric assays, the DNSA assay is also prone to 
some interference. For example, substances such as uric acid and polyphenols 
were reported to reduce DNSA in the presence of glucose (83). It was 
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proposed that the presence of phenols, in addition to the DNSA reagent, 
increases colour intensity during the colour development stage. Similarly, a 
reduction in the amino acid cysteine was also reported to interfere with the 
DNSA assay (86). In addition, since this technique requires high temperatures 
for the DNSA reagent and reducing sugars to develop colour, it is not 
convenient to conduct the assay directly onto the 96-well microtiter plate. To 
measure reaction kinetics, multiple samples need to be taken from the reaction 
mixture to carry out colour development with DNSA subsequently.  
Therefore, this method is comparatively quite tedious and requires a 
relatively long time, especially when it is used for screening a large number of 
samples. In addition, its sensitivity seems to be easily affected by several 
factors. For example, the nature of the buffer that is used to dilute the enzyme 
has been shown to decrease the sensitivity of the DNSA assay; whereas the 
addition of metals like manganous sulphate, calcium nitrate, and cobalt nitrate 
increases its sensitivity (87). At low substrate concentrations, results obtained 
from the DNSA assay also reveal inaccuracies (82, 88). Several studies found 
that the DNSA assay consistently produced significantly higher values (about 
40-50 % higher) of reducing sugars, than the actual number or compared to the 
results obtained from the DNSA assay, hence resulting in an overestimation of 
enzymatic activity (88-90). The magnitude of overestimation is dependent on 
the type of enzymes being tested, and the cause of the overestimation has been 
attributed to the instability of polysaccharides under the severe conditions of 
the assay, which involve high temperature and a strong alkaline medium (89). 
The harsh conditions cause the products of the enzyme to be decomposed by 




Figure 4. The DNSA assay for determining reducing sugar content (adapted from 
Wong and Huang, 2013) (91). 
 
b. Nelson-Somogyi assay (92, 93) 
The reducing sugar, when heated with alkaline copper tartrate, reduces 
the copper from cupric to cuprous oxide, which is treated with arsenomolybdic 
acid (Folin reagent) to develop intense molybdenum blue that can be 
monitored at 620 nm. Since this reaction is not stoichiometric, it has to be 
compared with a set of standard curves. Although the Nelson-Somogyi assay 
is deemed less convenient as compared to the DNSA assay, it has been 




CNP) (94, 95) 
This method uses the synthetic substrate Gal-G2-α-CNP, which is 
exclusively cleaved by α-amylase at the aglycone bond, resulting in two 
products: β-D-galactopyranisylmaltose and 2-chloro-4-nitrophenol (CNP). 
20 
 
The release of CNP can be detected and quantified using absorbance changes 
at 402 nm.  
This method is relatively simple in comparison to the DNSA or 
chromatographic methods. However, the downside of this technique is that the 
substrate is synthetic, and the interaction between enzyme and substrate may 
be very different as compared to natural ones.  Further validation of this 
method is thus needed to remove this possibility. 
 
Figure 5. Structure of Gal-G2-α-CNP and its reaction with α-amylase. 
 
d. Capillary electrophoresis (CE) (96, 97)  
The CE technique has been used to study interactions between drugs 
and various proteins, including enzymes. There are two major types of 
methodologies for CE: (1) affinity CE and (2) incubation method (96). CE 
uses evidence of molecular interactions between components via the direct 
detection of a complex from an equilibrium mixture, where the formation of 
complexes will result in a peak in the chromatogram. In affinity CE, the ligand 
is incorporated into the running buffer at increasing concentrations, obtaining 
the chromatograms for the protein solution. The shift in the migration time of 
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the peak area is taken as evidence for a potential interaction between the 
ligand and enzyme. For the incubation method, the enzyme and the ligand are 
incubated in the solution, which is then subjected to electrophoresis. A strong 
and stable binding of the emergent ligand-protein complex will form a peak in 
the chromatogram (97).  
However, this technique may not yet be widely accepted due to the 
high cost of the instrument, and in order to increase its sensitivity, laser 
fluorescence, which is technically demanding to set up, is needed. An 
additional difficulty of this method is that if the interacting molecules show 
large differences in their mobility, it would be hard to detect both free and 
bound species in the same electrophoretic run. This is especially so when the 
interacting molecules have opposite charges (98).  
e. Iodine-starch colorimetric method (99, 100)  
This method is based on the stainability of residual starch and its 
hydrolytic products after starch digestion. The maltodextrin products of 
amylolytic activity may not have equal complexing ability with iodine. That 
is, each sample possesses different maltodextrin compositions, which results 
in a variety of obtainable iodine stains before reaching its achromic point, 
which may be a source of misleading results. In addition, methods used within 
the literature (89-91) showed diverse iodine concentrations being applied, 
which range from 3 µM (101) to 0.25 mM (102), and the wavelength used to 
measure colour development varies from 550 nm (102) to 700 nm (99). Since 
iodine is a mild oxidant, it might be possible that some antioxidants in the 
sample may react with iodine and cause interference.  
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1.7.2 Assays to determine α-glucosidase activity 
a. Glucose oxidase/peroxidase (GOP) method  
The GOP uses glucose oxidase to catalyse the oxidation of α-D-
glucose to gluconic acid, with the formation of hydrogen peroxide. The 
oxygen that peroxidase liberates from hydrogen peroxide reacts with 
chromophores (e.g. o-dianisidine) to produce products which can be measured 
using UV-VIS absorbance at specific wavelengths (e.g. 540 nm) (Figure 6). 
The advantages of this assay are that the methodology is simple and low-cost, 
which allows it to be applied as a HTS method. Additionally, it also uses 
natural substrates like maltose and sucrose, and it is highly selective towards 
glucose. Conversely, the limitations of this assay include its susceptibility 
towards interference, especially from reducing substances like polyphenols. In 
particular, flavonoids with structural characteristics of the dihydroxyl groups 
in the ortho position in the B-ring were shown to cause strong interference 
within this assay (103). As such, this seriously hampers its applicability to 
screen through samples containing reductants (for example botanical extracts).  
 





b. p-Nitrophenyl-α-D-glucopyranoside assay 
In the human digestion tract, maltose is hydrolyzed by α-glucosidase to 
produce glucose as its product. However, because glucose cannot be detected 
by ultraviolet light directly, pNPG, a synthetic substrate, is frequently used 
instead of maltose to measure the activity of α-glucosidase. The substrate 
pNPG is cleaved by α-glucosidase at the α-(1, 4) linkage, which releases p-
nitrophenol. Also, under basic conditions, p-nitrophenol dissociates to p-
nitrophenolate, and this product can be measured at a UV-absorbance of 405 
nm (Figure 7). This method is only suitable for end point readings; it cannot 
be monitored in real time because the reaction mixture needs to be sampled 
and treated with a base to form the yellow p-nitrophenolate. In order to 
simplify the method for HTS application, the process was modified by 
removing the second step of alkalinisation. However, without the alkalisation 
step, the assay is much less sensitive (104). In addition, the short wavelength 
of this assay makes it prone to background interference from food matrices 
like black tea infusions that contain natural yellow pigments like flavonoids 






Figure 7. pNPG‟s α-(1,4) linkage cleaved by α-glucosidase to release p-nitrophenol 
and, under basic conditions, dissociates to p-nitrophenolate which can be measured at 
λ = 405 nm (adapted from Wong & Huang, 2013) (91). 
 
1.7.3 Physical property-based methods to determine enzyme inhibition 
a. Viscosity (102, 105)  
The viscometric assay is based on the decrease in the viscosity of 
starch solution during the enzymatic reaction, by determining the graph of the 
decrease in viscosity with time. This method is considered to be a sensitive 
technique which is suitable for monitoring α-amylase activity in a variety of 
fluids, due to its lack of interference with reducing sugar. A calibration curve 
is constructed in order to express enzyme activity in absolute terms or the 
number of catalytic events in unit time (IU). Its drawback is that it is too time-
consuming to be used routinely.  
b. Turbidity 
The turbidity assay is based on the optical density of a sample fluid 
which arises from the interaction of light and insoluble particles. This physical 
parameter has been applied to monitor cell growth dynamics in 
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microbiological and yeast cell studies, by applying the UV-VIS 
spectrophotometer (106, 107). The insoluble particles in the samples will 
interfere with light transmittance, which relates to thier size, shape, 
composition of the particles and the wavelength of the incident light (108).  
The relationship between absorbance and transmittance is expressed through 
Equation 1: 
         
[ ]          
⁄   (Equation 1) 
 
where A: absorbance, T: transmission, I: light passing through the sample and 
Io: light entering the sample. 
This method has recently been adapted to a HTS format for starch 
hydrolase inhibitors, and can be applied to rapidly quantify food and botanical 
samples for inhibition (109-113). The advantages of applying this assay for 
enzyme inhibition is that starch, a natural substrate, is used instead of synthetic 
ones, which is more representative of the reactions taking place in the human 
body, and different types of enzymes (e.g.α-amylase and α-glucosidase) can 
be tested using the same assay.  
1.8 Plant-based medicinal therapy 
It was estimated that about two-thirds of the world‟s population rely on 
health care from sources other than conventional biomedicine (114). 
Moreover, the WHO also reported that 80 % of the population in the Asian 
region depends on traditional medicine as their primary health care (6). 
Complementary and alternative medicine, which includes the use of botanical 
and natural dietary supplements, have sparked public interest due to their 
26 
 
historicity, effectiveness, fewer side effects and lower cost (115). They refer to 
a broad range of healing philosophies, approaches and therapies outside 
conventional medicine that stem from different indigenous systems of 
medicine like ayurveda, kampo, native American medicine, traditional 
Chinese medicine (TCM), unani, traditional Hawaiian medicine and many 
others. TCM, for instance, is an ancient Chinese medicinal system which has 
existed since five thousand years ago. It uses the Yin-Yang theory to diagnose 
human diseases and many herbs were documented for use in disease treatment. 
In TCM, the etiology of diabetes mellitus is identified as having a lack of qi, 
toxin retention and blood stasis in the body (115). The search for drugs and 
botanical supplements derived from plants has intensified in recent years to 
search for possible “leads” for the treatment of diabetes. Screening for novel 
starch hydrolase inhibitors has been carried out in a variety of edible medicinal 
plants from different regions like China (116), India (117, 118), the 
Mediterranean region (119), Brazil (120), Jordan (121), Malaysia  (122, 123), 
Nepal  (61, 124) and South Africa  (125).  
A large proportion of the world‟s recognized medicinal plants are 
derived from tropical forests. For example, approximately half (125,000) of 
the world‟s flowering plant species live in tropical forests (126). Tropical 
botanicals have evolved sophisticated chemicals to protect themselves from 
natural enemies, to subdue prey or to survive in a variety of ecosystems; hence 
they are very biodiverse in their chemical composition, leading to them having 
a significant role to play in being able to provide new leads in drug discovery. 
Nonetheless, despite their richness in biochemical resources, the potential of 
large areas of tropical rainforests remains virtually untapped. This can be seen 
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in the small percentage of drugs being approved as new compounds. To date, 
it was estimated that only 1 % of tropical species have been studied for their 
pharmaceutical potential and about 50 drugs are derived from tropical plants 
(126).   
Despite the slow progress of drug discovery in tropical botanicals, 
there have been several promising discoveries occurring almost exclusively in 
tropical forests. One example is the anti-AIDS compound produced by the 
Malaysian tree, a member of the tropical Garcinia family (Guttiferae-
Clusiaceae). The active compound was found to be (˗)-calanolide B and (+)-
Calanolide A from C.lanigerum whereby (˗)-calanolide B was found to be 
slightly less active than (+)-Calanolide A. (+)-Calanolide A has been 
synthesized, and is currently in Phase II of clinical trials (127).  This is just a 
hint of the massive potential that is hidden within tropical rainforests. 
Correspondingly, there are continuing issues of conservation of ethnobotanical 
data and biodiversity, and the urgency to expand exploration of these 
resources as a source of novel bioactive agents. With an increasing awareness 
of the value of tropical botanicals, there are concerted efforts from 
governmental agencies, universities and countries to protect, conserve, study 
and develop novel drugs that would be of great value to human beings.   
1.9 Starch hydrolase inhibitors 
1.9.1 Acarbose 
Acarbose is currently one of the strongest starch digestion blockers, 
which broadly inhibit starch hydrolases like glucoamylase, amylase, 
dextrinase, maltase and sucrose (128).  It is a pseudomaltotetraose that is a 
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bacterial secondary metabolite that is produced by strains of Streptomyces. 
Industrially, it is produced by strains of the general Actinoplanes sp. SE 
50/110 (129). Its chemical structure consists of an unsaturated amino cyclitol 
moiety (ring A), a deoxyhexose (ring B) or acarviosine together with ring A, 
and a normal maltose moiety (rings C and D) (Figure 8). Due to the presence 
of an inter-cyclic nitrogen atom in the acarviosine unit, the enzyme is unable 
to cleave the C-N linkage, thus preventing the enzyme from processing other 
ingested carbohydrates and therefore, glucose cannot be released for 
absorption. It has been suggested that due to its broad spectrum of inhibitory 
effects against hydrolases, it can result in serious gastrointestinal side-effects 
like flatulence and diarrhoea, which is due to undigested oligosaccharides 
entering the colon and being fermented by bacteria, generating gaseous 
metabolites as a result (130).  
 
Figure 8. Chemical structure of acarbose. 
 
1.9.2 Proanthocyanidins (PACs) 
PACs are the oligomeric and polymeric end products of the flavonoid 
biosynthetic pathway. PACs belong to the class of phenolic compounds, which 
are found to be ubiquitous in plants (fruits, bark, leaves and seeds) where they 
act as protectors against predation. In food, PACs are often linked to the 
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astringent characteristic associated with foods like wine and teas. As the name 
suggests, they are characterized by condensed polyphenols or tannins. Their 
basic building blocks are monomeric flavan-3-ol units and can be linked either 
through the C4-C8 or C4-C6 (B-type linkages). Another type of linkage, the 
A-type linkage, links the subunits via the C2-C7 and lacks two hydrogen 
atoms compared to the B-type PAC (131). Within the umbrella of 
proanthocyanidins, there are still different classes of PAC which depend on 
the substitution pattern of the monomeric flavan-3-ol units. PACs that 
exclusively consist of (epi)catechin units are termed procyanidins. 
Procyanidins can be found in many plants, notably in maritime pine bark, 
cinnamon, cocoa beans, grape seed and skin (132). These are the most 
abundant type of PACs that exist in plants.  In addition, a less common type of 
PACs are those that contain (epi)afzelechin and (epi)gallocatechin units, called 
propelargonidin and prodelphinidin respectively. Proanthocyanidins have been 
linked to quite a number of pharmacological attributes such as antiviral (133) 
and antimicrobial (134) activities. 
1.9.3 1-Deoxynojirimycin 
1-Deoxynojirinycin (1, 5-dideoxy-1, 5-iminoglucitol) (1-DNJ) is a D-
glucose analog and a strong inhibitor of glucohydrolases including 
glucoamylase (Figure 9). For example, 1-DNJ was shown to have a binding 
constant 10,000 times higher than that of glucose to Rhizopus glucoamylase 
(135). It is also known to be a tight-binding competitive inhibitor of sucrase 
(136). During the formation of the enzyme-inhibitor complex, 1-DNJ is 
assumed to become protonated at its nitrogen atom, leading to a positive 
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charge, thus mimicking the transition state formed during catalysis of substrate 
hydrolysis. This allows it to interact tightly with the negative charge in the 
catalytic centre  (137). 
 
Figure 9. Chemical structure of 1-DNJ. 
 
1.9.4 Thiosugars 
The presence of sulphur heteroatoms in thiosugars is responsible for 
biological activities. For example, a compound like 5-thio-D-glucopyranose is 
able to inhibit the release of insulin. In addition, thioxyloside has also been 
shown to be a potential anti-thrombotic agent (138, 139). These biological and 
physicochemical properties are attributed to several factors. Firstly, its sulphur 
atom possesses different electronic properties (electronegativity) as compared 
to oxygen atoms. Secondly, the electron density of sulphur atoms is more 
dispersed. Lastly, the carbon-sulphur bond is longer (ca. 1.8 Ӑ), and the C-S-C 
angle (ca. 95-100 º) is also smaller compared to the corresponding structure 
containing oxygen (138).  Combined together, it was postulated that perhaps 
these chemical attributes of sulphur analogs contribute to the biological 
activity of thio-sugars. For example, thio-sugars are able to easily form 
sulfoxides due to their ability to remove unsaturated bonds (deoxygenation) 
and are also oxidized easily to form disulfides (139). In contrast, however, 
there is also evidence to show that the removal of the sulphur group enhances 
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enzyme inhibitory activity as compared to the original sulphate counterpart 
(140).  
a. Salacinol 
Salacinol is a thio-sugar compound that has been isolated from an anti-
diabetic ayurvedic traditional medicine (Salacia reticulata). Its structure is 
comprised of a five member ring, with sulphur as the heteroatom (1, 4-
anhydro-4-thio-D-arabinitol), which contains a terminally sulphonylated four-
carbon aliphatic branched chain attached to the sulphur heteroatom (Figure 
10)  (139). Its special feature is that it possesses a positive charge carried by 
sulphur, which enables it to bind in a similar fashion as a protonated amine 
inhibitor to the α-glucosidase active sites (140). Experimental studies have 
shown this class of inhibitors to be very potent, whereby the Ki values were in 
the micro molar range (i.e., 0.1- 0.19 µM) and its bonds to ntMGAM were 
stronger compared to acarbose (Ki = 62 µM) (63, 141, 142). On the other hand, 
salacinol inhibitors are relatively poor inhibitors of human pancreatic -
amylase (Ki = 75 µM) compared to acarbose, which has a much lower Ki of 15 
nM (143). Hence, salacinol inhibitors are more selective towards α-
glucosidase rather than amylases, and acarbose has a stronger binding 
preference towards amylases compared to α-glucosidase.  
 





Kotalanol has a similar core structure to salacinol, which consists of 1, 
4-anhydro-4-thio-D-arabinitol. However, instead of its core structure being 
attached to a four-carbon aliphatic branched chain, it is attached to a seven-
carbon polyhydroxylated side chain containing six undefined stereogenic 
centres including the sulphonium centre (Figure 11) (144). Interestingly, an 
experimental study showed that the removal of the sulphate group enhances 
the inhibitory activity of kotalanol by approximately seven-fold, as compared 
to the original structure, to give a Ki of 0.03 ± 0.01 µM and 0.19 ± 0.03 µM 
respectively (144). It was suggested that without the bulky sulphate group, the 
initial positional constraints imposed by the group would be removed, thus 
allowing the rest of the polyhydroxylated chain to make optimal contact with 
the ntMGAM active site. Additionally, results also showed that acyclic chains 
longer than four carbons, such as those found in kotalanol, do not significantly 
enhance the inhibitory properties of MGAM since the Ki of salacinol (0.19 ± 
0.02 µM) and kotalanol (0.19 ± 0.03 µM) are essentially the same (140).  
 




1.10 Research aims  
In view of the escalating rate of diabetes cases, the search for novel 
anti-diabetic bioactives from natural sources, particularly from tropical 
botanicals, has become an urgent matter. In vitro studies are usually the 
starting point in the search for novel bioactive compounds, and they lay the 
groundwork for future studies. It is not feasible to screen for bioactives via in 
vivo studies as they are too costly and time consuming. However, in vivo 
studies may be used to follow up on important „leads‟ generated by in vitro 
studies. As such, it is vital to choose the most suitable in vitro assay that 
mimics bodily reactions as closely as possible, in order for results to have any 
significant implication. In addition, these assays should be properly validated 
to generate reliable results and to avoid any false positives. Currently, the two 
most popular methods to screen for α-glucosidase inhibition are the pNPG and 
the GOP method.  
The first two objectives of this project are: 
(1) To evaluate the pNPG method by assessing the impact of the use of 
natural versus synthetic substrates on the inhibition constants of 
acarbose and 1-DNJ on α-glucosidase (Chapter 2).  
(2) To assess the impact of polyphenolic compounds commonly found 
in many botanicals on the GOP assay, in the context of screening for α-
glucosidase inhibitors (Chapter 3).  
Subsequently, suitable in vitro HTS assays were applied to screen through a 
total of 298 plant samples, which were collected from the Singapore Botanic 
Gardens, for starch hydrolase inhibition, total phenolic and proanthocyanidin 
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contents. This screening work was taken a step further in an in-depth study of 
characterizing inhibitors from the Etlingera elatior inflorescence by applying 
assay-guided fractionation and separation of polyphenolic compounds. Hence, 
the third and fourth objectives of this project are: 
(3) To screen and determine the inhibitory potency of starch hydrolase 
inhibitors from edible botanicals collected from the Singapore Botanic 
Gardens (Chapter 4).  
(4) To characterize proanthocyanidins from Etlingera elatior 
inflorescence as strong starch hydrolase inhibitors (Chapter 5).  
Currently, there are several conventional starch hydrolase inhibitors that are 
effective but cause undesirable side-effects, like flatulence and diarrhoea. As 
such, the final part of the project aims to address this issue by exploring the 
potential of utilizing compounds (e.g. EGCG) that are available in common 
foods like green tea to potentiate and/or synergize the potency of conventional 
drugs.  The final objective of this study is: 
(5) To understand the synergistic mechanisms and potentiating action 
of epigallocatechin gallate towards acarbose and 1-DNJ on the 


















Evaluation of the p-nitrophenyl α-D-
glucopyranoside assay  
2.1 Introduction 
Synthetic substrates have often been used as a substitute for natural 
ones due to the convenience of using them to measure enzyme inhibition. One 
such assay is the p-nitrophenyl α-D-glucopyranoside (pNPG) colorimetric 
assay. This assay has been extended to measure inhibition for many years and 
utilises a synthetic substrate to measure the activity of α-glucosidase. It can be 
cleaved by α-glucosidase at the α-(1, 4) linkage, which releases p-nitrophenol 
and under basic conditions, and dissociates to p-nitrophenolate. This product 
can be measured at a UV-absorbance of 405 nm. 
An important factor that has often been disregarded in selecting assays 
to test for starch hydrolase inhibition is the choice of substrates. Ideally, the 
substrates should be physiologically relevant in order for the results to be 
reliable, and to have accurate implications. In particular, Ki is an important 
constant which measures the dissociation for the enzyme-inhibitor complex, 
and Ki' is the inhibition constant for the enzyme-inhibitor-substrate complex. 
In other words, for a reversible inhibitor, Ki gives an indication of the binding 
affinity between the enzyme and the inhibitor. The smaller the Ki, the tighter 
the binding between the enzyme and the inhibitor, thus the stronger the 
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inhibitory activity. There is a direct relationship between Ki and IC50 for 
competitive inhibitors, as shown by Equation 2 (145): 
        (  
[ ]
  
) (Equation 2) 
Currently, there has not been any research which addresses the issue of 
the validity of the pNPG assay. This study aims to compare the use of 
different substrates (i.e. synthetic vs. native) and how this affects the inhibitor 
constants. The use of native (maltose) and synthetic (pNPG) substrates will be 
used to test for the inhibitor constants (Ki and Ki
'
) of two well-known α-
glucosidase inhibitors (acarbose and 1-deoxynojirimycin). 
2.2 Materials and methods 
2.2.1 Reagents and instruments 
Acarbose (A8980), 1-deoxynojirimycin hydrochloride (D9305), a 
glucose assay kit (glucose oxidase/peroxidase reagent G3660; o-dianisidine 
reagent D2679), α-glucosidase from intestinal acetone powders from rats 
(I1630), and 4-nitrophenyl-α-D-glucopyranoside (N1377) were obtained from 
Sigma-Aldrich Chemical Co. (St. Louis, MO). Absorbance at 540 nm for the 
GOP method and 405 nm for the pNPG method was measured by a microplate 
reader (Bio-Tek Instruments Inc., Winooski, VT). A sodium phosphate buffer 
(pH 6.9; 0.1M) was utilized. 
2.2.2 Glucose oxidase/ peroxidase method 
α-Glucosidase (50 µL) was incubated with 125 µL inhibitor (final 
concentration of acarbose and 1-DNJ was 0.096, 0.19, 0.38, 0.77 µM and 0.06, 
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0.12, 0.24, 0.48 µM, respectively) for 5 min before 150 µL of maltose (final 
concentration of 13.8, 6.9, 3.5, 1.7, 0.87 and 0.4 mM) was added to initiate the 
reaction. The reaction mixture (40 µL) was sampled at 0, 1, 2, 3, 4 min and 
inactivated by adding 80 µL of tris-HCl (pH 7.0, 1 M final concentration). The 
deactivated mixture (40 µL) and glucose reagent (120 µL) were allowed to 
react for 30 min before the reaction was stopped with H2SO4 (120 µL, 6M). 
Absorbance was read at 540 nm. 
2.2.3 p-Nitrophenyl α-D-glucopyranoside method 
α-Glucosidase solution (120 µL) was incubated with 300 µL of 
inhibitor (final concentrations of acarbose and 1-DNJ were 0.096, 0.19, 0.38, 
0.77, 1.54 mM and 0.06, 0.12, 0.24, 0.48, 0.96 µM, respectively) for 5 min. 
pNPG (360 µL, final concentration was 6.9, 3.45, 1.7, 0.87, 0.43, 0.22 mM) 
was used to initiate the reaction. The reaction mixture (150 µL) was drawn at 
0, 5, 10, 15, 20 min and deactivated with the addition of 50 µL of 0.5 M 
Na2CO3. The absorbance was read at 400 nm. 
2.2.4 Graphical methods for determining the mode of enzyme inhibition, 
Ki and Ki' 
The Km
app
 method was used to estimate both the Ki aand Ki
'
. 
Complementary to this, the Dixon method estimates the Ki, whereas the 
Cornish-Bowden method gives the Ki' and mode of inhibition of the inhibitor. 








 method is based on the Michaelis-Menten (Equation 3). 
Each experimental data point, with varying substrate concentration and rates, 
was fitted individually using nonlinear regression to Equation 3, to obtain the 
Km
app 
value, as well as estimates of Vmax. 
   
      [ ]
  
    [ ]
  (Equation 3) 
Subsequently, estimates of Ki were obtained from a linear regression 
plot of Km
app
/Vmax (slope) as a function of inhibitor concentration [I], whereby 
Ki was obtained graphically from the intercept of the x-axis. Equation 4 
describes this relationship (146). Ki' can be determined using a plot of 1/Vmax 
as a function of [I] and its value was determined from the x-intercept.  
  
   
    
  
   [ ]
       
 
  
    
  (Equation 4) 
2.2.4.2 Dixon method 
The initial reaction rates were obtained experimentally with various 
substrate concentrations. The initial rates were used to estimate the Km and 
Vmax by linear transformation of the original Michaelis-Menten equation of v = 
(Vmax S)/(Km +S). A new set of calculated initial rates was obtained from the 
Michaelis-Menten equation, taking into account the square of the difference 
between the experimental initial rates and the calculated initial rates. The 
calculated initial rates were then used to generate the Dixon plot with the 
reciprocal of the rate of product formation (1/v) versus inhibitor concentration, 
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[I] at various substrate concentrations [S]. The plot yields a series of straight 
lines that intersect at a unique point, where (i) coordinate are the –Ki. Hence Ki 
can be read directly off the plot, or it may be obtained by solving two sets of 
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)  (Equation 5) 
2.2.4.3 Cornish-Bowden method 
This method is built on the assumption that all common types of 
inhibition are derived from linear mixed inhibition as a general case, where the 
rate 𝓿 is dependent on the substrate concentration [S] and the i value of the 
inhibitor, in accordance with Equation 6.  
   
  
  (  
 
  
 ) [ ](  
 
   
)
  (Equation 6) 
The Cornish-Bowden plot is derived from the rate equation described in 
Equation 6, which takes s/v against the inhibitor concentration i. From 
Equation 6, V is the limiting rate, Km is the Michaelis constant, Ki is the 
dissociation constant for the EI complex (or competitive inhibition constant) 
and Ki′ is that of the EIS complex (or the uncompetitive inhibition constant). 
This plot has a similar appearance to the Dixon plot; however, the i coordinate 















   
) (Equation 7) 
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From this plot, the mode of inhibition may be determined as well. 
Since Ki′ for the competitive inhibitor equals , the lines are parallel and there 
is no intersection between them. For mixed or non-competitive inhibition, the 
lines converge and intersect on the i axis.  
2.2.5 Statistical analysis 
Statistical analysis was performed using SPSS software. The Ki and Ki′ 
values are given as means ± standard deviations (SDs). Significant differences 
between means were analysed using one-way ANOVA (Duncan test) at p < 
0.05 level.  
2.3 Results and discussion 
Using the Dixon method as outlined in Section  2.2.4.2, Figure 12A 
shows the reciprocal of the initial rates of product formation (1/v) at various 
maltose concentrations (0.4, 0.9, 1.7, 3.5 and 6.9 mM) which were plotted 
against various acarbose concentrations (0, 0.096, 0.19, 0.38 µM). Linear 
regression equations were obtained for each substrate concentration and the 
negative of the x-axis value at the point of intersection between the straight 
lines denotes the Ki. Using the Dixon plot, the Ki of acarbose, using maltose as 
the substrate, was determined to be 0.07 ± 0.01 µM. To confirm this value, a 
different method (  
   ) as outlined in Section 2.2.4.1 (Figure 12D) was 
used to calculate the Ki, which was found to be 0.07 ± 0.004 µM. In addition, 
the   
    method was also applied to calculate the Ki′, which was 0.83 ± 0.16 
µM (Figure 12C). In addition, the Cornish-Bowden plot shows parallel lines 




Figure 13 shows the inhibition kinetic plots of acarbose with pNPG as 
the substrate. The Dixon plot in Figure 13A indicates that the lines intersect at 
I = 0.13 ± 0.01 mM which is the Ki. Similarly, Figure 13D also shows the line 
intersecting on the x-axis, giving a Ki of 0.13 ± 0.015 mM. Ki' was estimated 
to be 1.8 ± 0.2 mM by the  
    method (Figure 13C). Finally, Figure 13B 
shows that the curves are parallel to one another, which indicates that acarbose 
is a competitive inhibitor of α-glucosidase when pNPG is used as the 
substrate, which is the same as when maltose is used as the substrate. Hence, 
this result demonstrates that for acarbose, the use of a different substrate did 
not change its mode of inhibition.   
 
Figure 12. Inhibition kinetic plots of acarbose using maltose as the substrate: (a) 
Dixon plot of reciprocal rates of the hydrolysis of maltose (1/v) versus acarbose 
concentration [I]. The line intersection provides a measure of Ki. (b) Cornish-Bowden 
plot (s/v vs. I). (c) Plot of 1/Vmax vs. [I] to determine Ki′ of α-glucosidase. (d) Plot of 
Kmapp/Vmax vs. [I] to determine Ki of α-glucosidase. 
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Figure 13. Inhibition kinetic plots of acarbose using pNPG as the substrate: (a) Dixon 
plot of reciprocal rates of 4-nitrophenol release (1/v) versus acarbose concentration 
[I]. (b) Cornish-Bowden plot ([S]/v vs. I). (c) Plot of 1/Vmax vs. [I] to determine Ki' of 
α-glucosidase. (d) A plot of  
   ) /Vmax vs. [I] to determine Ki of α-glucosidase. 
 
The inhibition kinetic plots of 1-DNJ with maltose as the substrate are 
shown in Figure 14. By using the Dixon plot (Figure 14A), a Ki of 0.01 ± 
0.008 µM, where the lines intersect one another, was estimated. The calculated 
Ki by the   
    method gave a value that was slightly higher (Ki = 0.024 ± 
0.0012 µM) (Figure 14D). Ki′ values, as determined by the   
     (Figure 
14C), and Cornish-Bowden method, were 0.07 ± 0.019 and 0.07 ± 0.005 µM 
respectively. The mode of inhibition for 1-DNJ was shown to be that of 
mixed-type inhibition, as seen through the converging lines (Figure 14B).  
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Figure 14. Inhibition kinetic plots of 1-DNJ using maltose as the substrate: (a) Dixon 
plot of reciprocal rates of  the hydrolysis of maltose (1/v) versus 1-DNJ concentration 
[I]. (b) Cornish-Bowden plot ([S]/v vs. I). (c) Plot of 1/Vmax vs. [I] to determine the 
Ki′ of α-glucosidase. (d) Plot of   
   )/Vmax vs. [I] to determine the Ki of α-
glucosidase. 
 
Figure 15 shows the inhibition kinetic plots of 1-DNJ with pNPG as 
the substrate. Ki, as determined by the   
     (Figure 15D) and Dixon plot 
(Figure 15A), were 0.1 ± 0.06 and 0.18 ± 0.04 µM respectively. On the other 
hand, Ki′ as measured by   
     (Figure 15C) and Cornish-Bowden methods 
were 0.16 ± 0.011 and 0.16 ± 0.006 µM respectively. The Cornish-Bowden 
plot in Figure 15B also shows converging lines, which indicate that 1-DNJ 
exhibits mixed-type inhibition activity with pNPG as the substrate. Hence, this 
demonstrates that the type of substrate utilised does not influence the mode of 
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Figure 15. Inhibition kinetic plots of 1-DNJ using pNPG as the substrate: (a) Dixon 
plot of reciprocal rates of 4-nitrophenol release (1/v) versus 1-DNJ concentration [I]. 
(b) Cornish-Bowden plot ([S]/v vs. I). (c) Plot of 1/Vmax vs. [I] to determine the Ki′ of 
α-glucosidase. (d) Plot of  
   
/Vmax vs. [I] to determine the Ki of α-glucosidase. 
 
Table 1 summarizes the results of inhibition kinetics parameters for 1-
DNJ and acarbose; both are known α-glucosidase inhibitors with applications 
in anti-diabetic medicine. Overall, there were large differences in the Ki and 
Ki' of both inhibitors, 1-DNJ and acarbose, when different substrates were 
used. The use of pNPG as substrate resulted in a much larger Ki compared to 
when maltose was used. For example, Ki values, calculated from the Dixon 
method of 1-DNJ when pNPG was used (0.18 ± 0.04 µM), were 
approximately 20 times larger than the calculated Ki when maltose was used 
(0.01 ± 0.008 µM). An even more elaborate difference was seen in the Ki of 
acarbose with different substrates. Ki values of acarbose, estimated using the 
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Dixon method when maltose was used, were three orders of magnitude smaller 
(0.07 ± 0.01 µM) than the Ki values when pNPG was used (130 ± 15 µM).  
 
Table 1. Ki and Ki′ of 1-DNJ and acarbose using Kmapp, Dixon and Cornish-Bowden 
methods with either maltose or pNPG as the substrate. 
Inhibitor Substrate                                                           Estimated Ki (µM) 
  
            
   
 Dixon Cornish-Bowden 
Ki Ki'
 Ki Ki' Inhibition mode 
1-DNJ § 
Maltose 0.024  ± 0.0012a 0.07 ± 0.019 a 0.01 ± 0.008 a 0.07 ± 0.005 a Mixed 
pNPG 0.1 ± 0.06 b 0.16 ± 0.011b 0.18 ± 0.04 b 0.16 ± 0.006 b Mixed 
Acarbose  
Maltose 0.07 ± 0.004 c 0.83 ± 0.16 c 0.07 ± 0.01c  N/A Competitive 
pNPG 130 ± 10 d 1800 ± 200 d 130 ± 15 d N/A Competitive 
 
§ Different superscript letters (a and b) indicate significant differences (p < 0.05) in Ki or Ki' of 1-DNJ with different substrates. 
 Different superscript letters (c and d) indicate significant differences (p < 0.05) in Ki or Ki' of acarbose with different substrates. 
 
The mode of inhibition was found to be consistent for both acarbose 
and 1-DNJ, regardless of the type of substrate used. Acarbose consistently 
displayed competitive inhibition, whereas 1-DNJ displayed mixed inhibition 
of α-glucosidase. For acarbose, it acted as a competitive inhibitor towards both 
substrates but surprisingly, the Ki differed greatly. This finding does not 
correspond to the classical model for competitive inhibition, where the 
inhibitor binds only to the free enzyme, in contrast to mixed inhibition 
whereby the inhibitor is able to bind to both the free enzyme as well as the 
enzyme-substrate complex. Therefore, following this model for competitive 
inhibition, Ki should be constant regardless of the type of substrate used. We 
propose that the difference in Ki when different substrates were used was due 
to acarbose and 1-DNJ competing more easily with maltose as compared to 
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pNPG. This can be seen from the more rapid increase in Km for maltose as the 
concentration of inhibitor within the reaction system increases. This finding, 
however, seem to be in conflict with other literature findings whereby maltose 
was shown to have a higher affinity towards the active site of the enzyme than 
the synthetic pNPG (79, 147). Hence, in theory, inhibitors would be shown to 
be less potent when maltose is used as the substrate as compared to when 
pNPG is used, due to the strong affinity of maltose towards the enzyme and 
inhibitors not being able to compete as well. It is possible that there may have 
been a change in the pH optima of the enzymes when synthetic substrates 
were used. It was shown previously that the pH optima of α-amylases were 
higher with synthetic than with natural substrates (79). A change in the pH 
may very well change the enzyme‟s structure, which may affect the interaction 
between the enzyme and inhibitor such that the inhibitor may bind more 
weakly. In addition, the synthetic substrate pNPG had very low solubility at 
room temperature, but improved with warming. Consequently, the activity 
measured with the synthetic substrate was much lower than with the natural 
substrate.   
Furthermore, from the mathematical relationship outlined in Equation 
2, we can see that the IC50 of an inhibitor is directly related to the Ki. Hence, a 
larger Ki would result in a larger IC50, and the implications of a significantly 
different Ki would mean that the IC50 calculated when pNPG was used as the 
substrate would reveal pNPG as a less potent inhibitor compared to when 




Ki and Ki′ of acarbose and 1-DNJ were determined and compared by 
applying either natural substrate (maltose) or synthetic substrate (pNPG). The 
Ki measured was consistently higher for both inhibitors when pNPG was used, 
as compared to when maltose was applied as the substrate. A larger Ki 
translates to larger IC50 (i.e. lower potency), which may not be a true depiction 
of the activity of an inhibitor. These results also show that the mode of 
inhibition remains the same despite the change in substrate.  This study 
demonstrates the importance of choosing the right substrate; natural substrates 
should be used instead of synthetic ones in order for results to be 

















Assessment of the degree of interference from 
polyphenolic compounds on glucose 
oxidase/peroxidase assay  
3.1 Introduction 
Due to the increasing global population of type two diabetes, research 
on finding ways in mitigating this dreadful disease have intensified in recent 
years (148).  One way to control hyperglycaemia is through starch hydrolase 
inhibitors from edible plants, which contain structurally diverse α-glucosidase 
inhibitors including sugar mimics (149) and polyphenolic compounds (150, 
151). To uncover novel α-glucosidase inhibitors from plants, particularly 
edible plants, pNPG and GOP bi-enzyme assay are widely applied as 
convenient guides to fractionation and purification of inhibitors. While pNPG 
assay uses a synthetic probe that may not be truly reflective of natural 
substrates of the enzymes, the GOP assay was developed initially to quantitate 
the amount of D-glucose in human fluids (152). Principally, this assay uses 
glucose oxidase to oxidize β-D-glucose by molecular oxygen to D-glucono-β-
lactone and hydrogen peroxide. In the presence of peroxidase (e.g. horseradish 
peroxidase), hydrogen peroxide reacts with colourless chromogenic molecules 
to form colourful dyes that can be quantified conveniently by colorimeters 
(Figure 16). Many chromogenic compounds have been used as substrates for 
horseradish peroxidase (153).  Among them, o-dianisidine has been more 
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widely applied than others. In acidic conditions, the oxidized o-dianisidine 
becomes rose-pink coloured with absorbance maximum at 540 nm (Figure 17) 
(154).  Due to its convenience, the GOP assay has been applied in many other 
systems including measurement of α-glucosidase activity and screening for its 
inhibitors.  
Although GOP assay is highly substrate specific and relatively 
convenient to utilize, it is highly susceptible to various interferences (155, 
156). The GOP assay utilizes two oxidases and involves complicated redox 
reaction mechanisms; as such any compounds that can inhibit the two 
enzymes or react with the reactive intermediates of reaction will cause 
interferences (157).   Indeed, there are scattered reports on the interference 
issue of the GOP assay. Using 4-aminoantipyrine and 3-hydroxybenzoic acid 
as chromogenic substrates in the GOP assay, it was recently found that green 
tea polyphenolic compounds cause interferences and lead to false negative 
results in blood serum glucose concentrations and the interference was 
suggested to be due to the radical scavenging activity of the polyphenolic 
compounds (158). In another study, polyphenols were also found to interfere 
because of their reducing activity (159). Despite the number of reports 
addressing the issue of interferences, GOP assay continues to be applied in the 
quantification of α-glucosidase inhibitory activity of natural products due to its 
convenience and selectivity of glucose (160).  Since, natural products often 
contain polyphenolic compounds, it is important to systematically address the 
scope and limitations of the GOP assay in quantifying botanical samples on α-
glucosidase inhibitory activity. Therefore, we investigated the interference of 
common polyphenolic compounds found in the plant kingdom on the degree 
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of interferences on GOP assays by adding sodium dodecyl sulfate (SDS) to 
stabilize meriquinone intermediates formed during the oxidation of o-
dianisidine by peroxidase. Our results reported herein will help researchers in 
using GOP assay in plant extracts to assess the suitability of the assays and 
provide a guide for avoiding unnecessary false results.  
 
Figure 16. Possible interference principles behind the GOP assay. 
 
3.2 Materials and methods 
3.2.1 Reagents and instruments  
Chemical reagents were obtained from commercial sources. These 
compounds include caffeic acid, ferulic acid,  rutin, apigenin, chrysin, 
coumaric acid, gallic acid, hesperedin, hesperetin, kaempferol, luteolin, morin, 
naringin, quercetin, hydrogen peroxide solution, o-dianisidine 
dihydrochloride, glucose oxidase, and peroxidase from horseradish (Sigma-
Aldrich, Singapore); 3, 5-dihydroxyflavone, 3, 7-dihydroxyflavone, 3', 3, 4-
trihydroxyflavone, 5, 3', 4'-trihydroxyflavone, 5, 7, 3', 4', 5'-
pentahydroxyflavone, 7, 3', 4'-trihydroxyflavone, 7, 8-dihydroxyflavone, 
fisetin, galangin, gossypetin, and myricetin (Indofine Chem. Co. California, 
USA); tannic acid (Merck, Germany); ascorbic acid,  chlorogenic acid 
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(Spectrum Chemical Co, Singapore). Microplate reader (Bio-Tek Instruments 
Inc., Winooski, VT) was used to measure the spectrophotometric readings.  
3.2.2 Generation of the meriquinone intermediate and its reactivity with 
polyphenolic compounds.  
o-Dianisidine (0.1 mM), SDS (1.0 mM), H2O2 (0.1 mM)  and 
peroxidase (0.25 units) in citrate buffer (pH 4) were reacted for one minute to 
generate the meriquinone intermediate, which was quantified by UV-
absorbance at 395 nm. Polyphenolic compounds with various concentrations 
were reacted with meriquinone. The decrease in the UV-absorbance over time 
was monitored for selected compounds including vitamin C, coumaric acid, 
caffeic acid, gallic acid and EGCG.  For the rest of samples, end point 
readings were carried out at 650 nm. The final concentrations of the 
polyphenolic compounds were kept at 100 µM. The absorbance readings were 
taken after 5 min of reaction. The degree of interference was quantified 
through Equation 8:  
% Interference = 100(Ablk-As)/Ablk  (Equation 8) 
where As is the absorbance of the reaction mixture of the sample with 
meriquinone at 650 nm, Ablk is the absorbance of blank (water).  
3.2.3 Determination of the radical scavenging activity using DPPH 
Antioxidant radical scavenging activities of the various polyphenolic 
compounds were determined by using the free radical DPPH microplate assay 
with methanol (161). DPPH reacts with an antioxidant which donates 
hydrogen and reduces DPPH. A stock solution of 0.1 mM DPPH dissolved in 
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methanol was prepared and the excess sample was stored in eppendorf tubes 
covered in aluminium foil and placed in the refrigerator until further use. The 
polyphenolic compounds were dissolved in DMSO and prepared at various 
concentrations (0.125, 0.25, 0.5, 1, 2, 4 and 8 mM). Briefly, 15 µL of the 
polyphenolic compounds at various concentrations were added in triplicate 
cells. Consequently, 285 µL of DPPH stock (0.1 mM) was added to the 96-
well plate using a multichannel pipettor.  The microplate was placed into the 
microplate reader and the change in absorbance was monitored at 517 nm. The 
results are expressed as IC50 which is the concentration which exhibits 50 % 
radical scavenging activity. The percentage of radical scavenging activity was 
quantified through Equation 9: 
                              [                   )          ] x 100  (Equation 9) 
Where ODcontrol is the optical density of the blank (DMSO) and ODsample is the 
optical density of the test sample.  
3.2.4 Statistical analysis  
All measurements were performed in triplicates and the results are 
expressed as mean ± standard deviation. Significant differences between 
means were analysed using one way ANOVA (Duncan test) at p < 0.05 level. 
3.3 Results and discussion 
During the quantification of α-glucosidase activity and measuring the 
activity of inhibitors, maltose or sucrose were hydrolysed into glucose (and 
fructose in the case of sucrose). The α-glucosidase activity was measured by 
the generated glucose by the GOP assay. The commonly used chromophore in 
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GOP assay is o-dianisidine, which is oxidized by peroxidase to give brown 
azo dye via a blue charge transfer complex meriquinone (Figure 17). The 
polyphenolic compounds may interfere with the assay by reacting with 
meriquinone, which will lead to false negatives of the glucose or false 
positives in α-glucosidase inhibitory activity. To assess the severity of 
interference by different polyphenolic compounds by reducing meriquinone 
intermediate, we applied SDS at pH 4 according to literature reports to 
stabilize the positively charged meriquinone intermediates through 
electrostatic interaction with the negatively charged surfactant (162, 163).
 
 
Figure 17. Reaction scheme of o-dianisidine oxidation. Hydrogen peroxide reacts 
with colorless reduced o-dianisidine in the presence of peroxidase to form the 
dianisidine quinonediimine intermediate. Application of SDS suspend the 
meriquinoid complex intermediate (λmax= 395; 650 nm). Irreversible coupling 
reaction with two quinonediimines to form the brown bisazobiphenyl product. 
Bisazobiphenyl product reacts with H2SO4 to form a more stable pink colored product 




3.3.1 Ascorbic acid  
When ascorbic acid was added to the meriquinone solution at 
concentrations of 25 µM and 50 µM (1:4 and 1:2 ratio with reference to 
H2O2), there was an initial marked decrease in absorbance but also a regain of 
the blue colour from 10 to 250 seconds (Figure 18A). Apparently, the 
ascorbic acid is consumed quickly by oxidation with meriquinone leading to 
the fading of blue colour. The increase in absorbance is due to the regeneration 
of meriquinone intermediates formed by enzymatic catalysed oxidation of o-
dianisidine as there was a surplus of H2O2. When ascorbic acid was added at a 
ratio of 1:1 with H2O2 (100 µM), there was a dramatic reduction in the 
meriquinone solution to a colourless solution without any regain of colour. 
This finding suggests that vitamin C only reacts with meriquinone but does not 
inhibit peroxidase. 
We further monitored the reduction kinetics of the meriquinone 
intermediate reaction with coumaric acid, caffeic acid, gallic acid, and 
epigallocatechin gallate with concentration equal to that of H2O2 (Figure 
18B). Coumaric acid with only one hydroxyl group (OH) did not show much 
reactivity, while caffeic acid can lead to 50% interference at steady state 
throughout the remaining time. A further addition of an OH group in gallic 
acid was shown to reduce 75% of the absorbance values, from 0.8 to 0.2. The 
dependency on the number of OH groups in the phenolic acid is consistent 
with the increasing reducing activity from mono to tri-OH moieties. These 
preliminary results prompted us to systematically evaluate the interference of 




Figure 18. (A) Reduction kinetics of the meriquinone structure monitored at 395 nm 
for 15 minutes at various stoichiometries of H2O2 concentration to ascorbic acid (ratio 
of 4:1, 2:1 and 1:1). (B) Reduction kinetics (monitored at 395 nm for 15 minutes) of 
the meriquinone structure of coumaric acid, caffeic acid, gallic acid, ascorbic acid and 
EGCG at stoichiometric ratio of 1:1 H2O2: sample concentration. 
 
3.3.2 Reduction of meriquinone intermediate by polyphenolic 
compounds  
To delineate the structure and activity relationship, we measured 31 
commonly found polyphenolic compounds and the results are shown in 
Figure 19 arranged by their structural groups. Each class of compounds will 
be discussed respectively. The degree of interferences was divided in three 
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groups whereby polyphenolic compounds with a % interference of less than 
20 would be classed as having “no interference” (grey colour). Degree of 
interference between 20-70 % are classed as the “intermediate interference” 
group (blue colour) and polyphenolic compounds with interference above 70 
% are considered to have “high interference” (red colour).  
Flavones. As shown in Figure 19A, chrysin and apigenin have no 
interference (p < 0.05) indicating that the A ring OH group at 5 and 7 
positions do not enable them in reduction of meriquinone. In contrast, 
apigenin isomer, 7 (or 5), 3′, 4′-trihydroxyflavone exhibit significant activity. 
This plus the fact that luteolin having a similar activity suggests that the 
catecholic unit is sufficient for the reduction of meriquinone. In agreement 
with this, 7, 8-dihydroxyflavone also has a comparable activity albeit it has 
only two OH groups. In this series, pentahydroxyflavone possesses the 
strongest activity because it has three ortho-OH groups at the B ring. 
Flavanones. The common flavanones naringin, hesperetin and its 
glycoside counterpart hesperedin all showed intermediate interference activity 
as shown in Figure 19B. The reason was that the B rings of the tested flavones 
do not contain catecholic units. Apparently, methoxylation of catechol unit 
will lead to a reduced activity. In addition, there was no difference between 
hesperidin and hesperetin suggesting that the OH group in C-7 position of the 
A ring does not contribute to the activity of reducing meriquinones. These 
flavanones do possess some antioxidant activity, although the activity is much 
weaker compared with many other flavonoids (164, 165).  Similar to the case 
of rutin, the glycosylation of hesperedin did not influence the interference 
percentage (p > 0.05). 
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Phenolic Acids. Coumaric acid shows a partial interference even 
though it only has one OH group, this is very different from that of 
isoflavones, which have multiple OH groups but only has very weak 
interferences (Figure 19C). In addition, ferulic acid and caffeic acid show 
stronger interferences that is comparable to that of chlorogenic acid. Gallic 
acid also exhibits strong interference. Therefore, it is reasonable to conclude 
that hydrolysable tannins, which are the major group of polyphenolic 
compounds in the plant kingdom, will also have strong interference because 
gallates are the main moiety in hydrolysable tannins. Indeed, tannic acid 
shows a strong interference. Similarly, caffeic acid has two OH groups 
arranged in the ortho position and was shown to have percent interference of 
88.91 ± 2.35 which was comparatively high. The percent interference of 
caffeic acid was not significantly different (p > 0.05) to that of gallic acid (due 
to the additional OH group) and ferulic acid (due to the CH3O group). In the 
case of ferulic acid, one methoxy substitution at the ortho position relative to 
the hydroxyl group slightly decreased the interference (84.89 ± 2.8), but the 
decrease was not significant (p > 0.05). Ortho substitution with an electron 
donor of a methoxy group stabilizes the aryloxyl radical and thus its 
antioxidative action. However, the impact of a methoxy group is far from 
being equivalent to the addition of a hydroxyl group. The removal of either the 
methoxyl or hydroxyl group results in the phenolic ring resulted in a sharp 
decrease in the % interference as seen by the coumaric acid structure. 
Monophenols are known to be less efficient in antioxidant activity (166, 167). 
 
Flavan-3-ols. Similar to previous reports, we found that all flavan-3-ols 
(catechins) exhibit strong interferences (Figure 19D). At the tested 
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concentration, there was no difference among the catechins. The catecholic 
units in the B ring and/or the ortho-trihydroxy groups in the B ring and galloyl 
units are certainly potent in reducing meriquinones (168). 
Flavonols. With eleven compounds, this group is the largest category 
and all of them exhibit a certain degree of interference (Figure 19E). The 
degree of interference is roughly correlated to the number of OH groups 
except rutin, which has four OH groups but the interference activity is much 
weaker than that of its aglycone quercetin. Therefore, 3-OH group contributes 
significantly to the activity. In this series, the ortho-OH group at B ring 
increase the activity as it is apparent by comparing the values of kaempferol 
and quercetin. 3, 5-dihydroxyflavone, 3, 7-dihydroxyflavone and galangin 
showed intermediate interference. These three compounds have a similar 
feature in that it lacks any hydroxy group in the B-ring of its structure but 
differ in the OH group present in the A and C-ring. The hydroxy position of 3, 
7-dihydroxyflavone showed a significantly stronger interference compared to 
3, 5- dihydroxyflavone. Galangin, which has OH groups on the 3, 5, 7-position 
did not significantly increase interference compared to 3, 7-dihydroxyflavone. 
The addition of a hydroxyl group (monohydroxyl substitution) in the B-ring as 
seen in kaempferol increased the percent interference significantly (p < 0.05). 
It has been proposed that the single 4‟-hydroxyl group in the B-ring has the 




phenoxyl radical formed could abstract an electron from the 
radical cation to generate a dication and the phenolate (166). The addition of 
another hydroxyl group in the 5' position of the B-ring as seen in myricetin did 
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not significantly (p > 0.05) alter the interference as compared to quercetin. 
This is on par with other studies, which have shown that the presence of a 
third hydroxyl group in the B-ring at C-5 position did not enhance the 
effectiveness of myricetin compared to quercetin (167). The stabilizing effect 
of the extra radical is provided by only one of the two hydroxyls ortho to the 
hydrogen-donating hydroxyl group (168). Studies have also suggested that a 
hydrogen atom is most likely donated from the 3-OH, which leads to a more 
stable radical tautomer (169, 170). The radical scavenging property of 
flavonoids has been attributed to the number of OH‟s that are present in the 








Figure 19. Interference of various compounds (represented in numerics) and 
subdivided according to their respective classes. (A) Flavones (B) Flavanones (C) 
Phenolic acids (D) Flavan-3-ols (E) Flavonols. Significant difference between means 
were analysed using one way ANOVA (Duncan test) where different alphabets 
represent significant differences at the p < 0.05 level. 
 
In addition, the configuration of the H-donating hydroxyl groups is 
also one of the main structural features, which influence the antioxidant 
capacity of phenolics (173).  Furthermore, compounds in the “high 
interference” group possess many OH groups that are in the ortho position. 
The ortho arrangement of OH groups causes the development of 
Intramolecular Hydrogen Bond which is able to stabilize the radical, leading to 
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a lower O-H Bond Dissociation Enthalpy (BDE). The BDE governs the ability 
of a particular flavonoid to donate hydrogen atoms and the lower the BDE 
value, the higher the ability of a flavonoid to donate hydrogen (174).  
3.3.3 Correlation of degree of interference and antioxidant activity 
measured by 2, 2-Diphenyl-1-picrylhydrazyl (DPPH) radical scavenging 
activity  
Since meriquinone is an oxidant and its reaction with polyphenolic 
compounds has some similarity to the reaction used in measuring the 
antioxidant activity as the DPPH assays. If there is a good correlation of 
interference and the DPPH assay, one might be able to apply the DPPH assay 
to conveniently distinguish the likelihood of interference of any given plant 
extracts. Therefore we attempted to correlate the degree of the interference and 
the IC50 of the polyphenolic compounds for DPPH assay and the results are 
shown in Figure 20. In general, those compounds with a high interference also 
had a high antioxidant activity (i.e. low IC50 of DPPH assay) but there was no 
linear correlation. Therefore, DPPH may be qualitatively applied to judge the 
potential interference of the GOP assay. Measuring the turbidity decrease 
during enzymatic starch hydrolysis is a faithful way to test enzyme activity 
and it is not subjective to interference due to reducing activity of the phenolic 
compounds. We applied this method to evaluate inhibitory activity of α-
glucosidase, and found that these compounds have no measurable activity. 








In conclusion, I have illustrated that the majority of polyphenolic 
compounds found in the plant kingdom have a significant interference on the 
GOP assay. Since the reaction with the free radical intermediate is likely to be 
a reduction reaction it is reasonable to assume that, radical scavengers will 
have a false positive interaction. This effectively makes the GOP assay not 
useful in measuring the α-glucosidase inhibition activity of botanical extracts. 
It is essential to test the interference first before applying the GOP assay for 
quantification of α-glucosidase activity.  Recently, our group developed a high 
throughput method for screening α-glucosidase and α-amylase inhibition 
activity of natural products using turbidity changes (175). In this assay, natural 
starch was applied as the substrate and acarbose was used as a reference 
standard. Since turbidity is a physical parameter of the starch solution, one 





Screening of edible plants from the Singapore 
Botanic Gardens for starch hydrolase inhibitors 
4.1 Introduction 
Plant-based medicinal therapy like that of TCM, Indian Ayurveda and 
Arabic unani has been applied since ancient times to treat or prevent different 
kinds of metabolic diseases. Moreover, herbal remedies seem to offer a gentler 
yet effective means of managing diseases like diabetes, but the actual 
mechanism or active compositions are not known. Although it is commonly 
believed that they hardly have any adverse effects on the body, verification 
through rigorous scientific research is required (176). Many of these medicinal 
plants originate from rainforests. Southeast Asian rainforests are known to be 
home to some hundreds of medicinal plants which are biochemically diverse, 
in addition to providing an important resource for natural medicine, as well as 
for discovering new cures. In fact, many of the currently available drugs are 
directly or indirectly derived from plants; for instance, the commercially 
available hypoglycaemic drug, metformin, is derived from Galega officinalis 
(177). There are about 800 plant species that have been reported to possess 
anti-diabetic properties (178). Yet it was estimated that less than 10% of these 
plant species have been investigated chemically (with less than 1% assessed in 




A 1991 report on diabetes by the World Health Organisation (WHO 
recommended that intensive research on the beneficial effects of medicinal 
plants be performed in order to capitalise on the medicinal benefits derived 
from their bioactive components.  In line with this recommendation, our study 
focuses on the screening of medicinal plants from the Southeast Asian region. 
The Healing Garden, launched in 2010, is located within the Singapore 
Botanic Gardens (SBG) and is considered to be one of the largest medicinal 
gardens in the Southeast Asia region, spanning 1.5 hectares. The Healing 
Garden showcases an extensive collection of over 500 species of medicinal 
plants that have been traditionally used in Southeast Asia and other tropical 
regions of the world. Our research will specifically be selecting for starch 
hydrolase inhibitors by applying high-throughput screening methods. One of 
the aims of this paper is to discover more specific and effective enzyme inhibitors 
(already an important area of investigation), particularly found in edible 
botanicals. This area of research is vital because conventional drugs like acarbose, 
which is a known AGH inhibitor when ingested, produces undesirable 
gastrointestinal side effects like diarrhoea, flatulence and abdominal pain, making 
it unpopular as an anti-diabetic drug (47). It was hypothesized that the reason 
behind the side effects caused by these drugs was because of their non-specificity 
in targeting different glycosidases, resulting in abnormal bacterial fermentation of 
undigested carbohydrates in the colon (48). Additionally, this study also screens 
for the total phenolic contents (TPC) of the various plant sample extracts. 
Polyphenolic compounds have been linked to an overall increase in glucose 
homeostasis and insulin resistance through various mechanisms like increasing 
insulin-dependent glucose uptake via GLUT4, protecting pancreatic β-cells 
against oxidative damage, inhibiting intestinal sodium-dependent glucose 
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transporters (SGLT1 and SGLT2) and several others (180). In order for the 
team to obtain a wide selection of medicinal plants, permission was obtained 
to launch a sampling exercise on plants grown in the Healing Gardens. 
4.2 Materials and methods 
4.2.1 Reagents and instruments 
Porcine pancreatic α-amylase (A3176, type VI-B), rat intestinal α-
glucosidase (I1630), corn starch (S4126), acarbose (A8980), Folin-Ciocalteu‟s 
phenol reagent, anhydrous sodium carbonate, gallic acid, 4-
dimethylaminocinnamaldehyde (D4506), and hydrochloric acid (37%) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Procyanidin A2 (min. 
99%) was purchased from Cfm Oska Tropitzsch (Marktredwitz, Germany).  
4.2.2 Collection, preparation and extraction of botanical materials 
The plant materials were collected between the periods of December 
2012 to July 2013 from the Healing Gardens located within SBG. The plants 
were authenticated by SBG and current plant names have been verified with 
The Plant List (www.theplantlist.org), which is a collaborative online database 
created and updated by the Royal Botanic Gardens, Kew and Missouri 
Botanical Garden. Samplings were done under the supervision of at least one 
SBG officer who also verified the identification of the plants. Immediately 
after the sample collection, parts of the plant (leaf, stem and flower) were 
separated, washed thoroughly and blotted dry to remove any possible trace of 
impurities or potential contamination. Subsequently, samples were frozen in a 
-20 ºC freezer, frozen dried and ground to powder with an electric grinder.  
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Each of the resulting powdered samples (0.5 g) were accurately 
weighed into a 50 mL centrifuge tube and extracted with 10 mL of solvent 
mixture acetone, methanol and water at a ratio of 2:2:1 (AMW; 2:2:1, v/v). 
Different groups of compounds, with varying polarities, respond to different 
mixtures of extraction-solvent systems, which will collectively influence the 
potency for enzyme inhibition. This particular solvent mixture was selected 
according to a previous study (109) that compared different extraction 
methods, such as 100 % water and 70 % ethanol. It was discovered that this 
solvent ratio of AMW; 2:2:1, v/v gave the highest enzyme inhibition activity; 
hence, this solvent mixture will be utilised in this study. The centrifuge tube 
was stirred vigorously with a vortex until all the powder was suspended within 
the solvent and this was followed by continuous extraction using a rotary 
shaker for 24 hours at room temperature. After the extraction, the samples 
were centrifuged at 4000 rpm/min for 15 minutes at 15 ºC, and the supernatant 
collected and filtered using filter paper. Volatiles were evaporated by a rotary 
evaporator and the dried residue weighed and further dissolved in AMW 
solvent mixture for further tests.  
4.2.3 Determination of total phenolic content (TPC) 
The TPC was estimated using the Folin-Ciocalteu reagent according to 
previous protocols (181, 182). Firstly, 20 µL of sample extract supernatants 
were diluted to appropriate levels and mixed with 100 µL of 10 % (v/v) F-C 
reagent, vortexed thoroughly and allowed to react for 15 minutes at room 
temperature. Sodium carbonate (80 µL, 700 mM) was added to the mixture 
and allowed to stand for 30 minutes at room temperature for colour 
development. Gallic acid was used as a standard (50 µM- 2.5 mM gallic acid 
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in 95 % v/v methanol) and the results are expressed in terms of gallic acid 
equivalents (GAE). Absorbance was read at 765 nm using a multi-detection 
microplate reader (Synergy HT, Bio-Tek).  
4.2.4 Determination of Proanthocyanidins content 
A validated and improved 4-dimethylaminocinnamaldehyde (DMAC) 
colourimetric method (183) was applied to estimate the concentration of 
proanthocyanidin in sample extracts. Acidified ethanol was prepared by 
adding concentrated (36 %) hydrochloric acid (12.5 mL) to distilled water 
(12.5 mL) and ethanol (75 mL, 91 %) in a glass bottle, and mixed. The DMAC 
reagent (0.1 %) was prepared by weighing 0.05 g of DMAC to 50 mL of 
acidified ethanol. For the analysis, the incubation chamber was pre-heated to 
25 ºC. Seventy microliters of control, standard, blanks and samples were 
dispensed into the well of a 96-well plat where the control is definted as the 
working solution without the test extract, the standard is procyanidin A2 
solution, the sample is the working solution with the test extract and the blank 
is the dissolving solvent for the standard. The DMAC reagent (210 µL) was 
added to the wells, bringing the final volume to 280 µL/well. Aliquots of stock 
solution (1.5 mL) of procyanidin A2 containing 1 mg was dissolved in 10 mL 
of ethanol (91 %) to give a final concentration of 100 µg/mL and stored in - 30 
ºC. During analysis, 250 µL of ethanol (91 %) was added to 1 mL of stock 
solution in a 1.5 mL conical tube, and vortexed to give a working solution of 
80 µg/mL procyanidin A2 solution. The working solution was diluted twice to 
generate a calibration standard curve (80, 40, 20, 10, 5, 2.5, 1.25 and 0.625 
µg/mL). Maximum absorbance readings were taken at 640 nm for 25 min 
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using a Synergy HT microplate reader. The results are expressed in terms of 
procyanidin A2 equivalents (PAE).  
4.2.5 High-throughput turbidity assay of α-amylase and α-glucosidase 
inhibition activity 
The inhibition activity was determined using a method that was 
previously established (175).  Aliquots of PPA powder were dissolved in 
phosphate buffer (0.1 M, pH 6.9, spiked with 50 ppm of CaCl2) to give a stock 
concentration of 4 mg/mL and stored in small vials at -30 ºC. The α-
glucosidases were extracted from rat intestinal acetone powder by dissolving 
0.5 g of the powder in 20 mL of phosphate buffer and stirred in an ice-bath for 
30 minutes before it was centrifuged at 2000 g at 4 ºC for 10 minutes. The 
supernatant was collected and stored at -30 ºC at aliquots of 250 µL as a stock 
solution until further use. During analysis, 200 µL of α-amylase / α-
glucosidase stock solution was diluted in 3.8 mL of phosphate buffer to give a 
working stock solution. Corn starch (0.5 g) was dispersed in 25 mL of 
phosphate buffer in a beaker and stirred through with a magnetic stirrer until it 
became a milky mixture. The starch suspension was then placed on a hotplate, 
for 2 min at 400 ºC with continued stirring at 300 rpm, until the solution 
reached boiling point to produce a gelatinized semi-translucent solution. In 
each well, 20 µL of PPA (0.2 mg/mL) was mixed with a series of 
concentration of plant extracts (20 µL) or acarbose as a positive control (final 
concentration of 40, 27, 18, 12, 8, 5, 3.5 and 2.3 µg/mL) and pre-incubated in 
the microplate reader for 15 minutes at 37 ºC.  
The reaction was initiated by adding 60 µL of the 2 % gelatinized corn 
starch to each well containing the pre-incubated enzyme-inhibitor mixture. 
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The 96-well plate was immediately placed onto the microplate reader, and the 
UV absorbance monitored at 660 nm for 2 hours, with one reading per 30 
seconds, and shaking to ensure sufficient mixing and to avoid starch 
sedimentation. The percentage inhibition is calculated by Equation 10 where 
AUCinhibitor is the area under the curve (AUC) of the inhibitor and AUCcontrol is 
the area under the curve without inhibitors. The IC50 is the inhibitor 
concentration required to produce 50 % inhibition. The concept of acarbose 
equivalence (AE) was applied and is defined by Equation 11. 
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4.3 Results and discussion 
The turbidity assay was shown to be an effective HTS that could assist 
in identifying bioactive compounds in botanicals. A total of 298 plant samples 
were initially collected from the Singapore Botanic Gardens and tested for α-
amylase and α-glucosidase inhibition. Preliminary screenings indicated that 
170 plants did not show any inhibitory activity. Based on literature reports, 
another 57 plants were deemed either inedible or toxic, leaving a total of 71 
plant samples that are “edible” and “medicinal”. “Edible” refers to the 
category of plants that can be eaten as everyday vegetables, whereas 
“medicinal” refers to plants that have been used as therapeutic agents (not 
limited to diabetes) by indigenous people. The IC50, acarbose equivalents (AE) 
of α-amylase and α-glucosidase inhibitory activity, TPC and PAC of the 71 
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edible plant extracts are summarized in Table 2. Out of the 71 edible plants 
that were screened, 14 showed promise in terms of their usage in traditional 
medicinal (which may or may not have been used traditionally to treat 
diabetes) and they all have varying strength of inhibitory activity against α-
amylase and α-glucosidase. These 14 plants are Antidesma ghaesembilla, 
Antidesma bunius, Mesua ferrea, Lepisanthes alata, Synsepalum dulcificum, 
Tamarindus indica, Azadirachta indica, Syzygium cumini, Chrysophyllum 
cainito, Garcinia mangostana, Laurus nobilis, Drobalanops aromatica, Atuna 
racemosa and Madhuca longifolia. Their traditional medicinal uses, enzyme 
inhibitory activity, PAC and TPC contents are described in greater detail in the 
following sections.     
In order to illustrate the potencies of each plant extract against both α-
amylase and α-glucosidase, Figure 21 shows a scatter plot between the AE of 
plant samples against α-glucosidase (y-axis) and α-amylase (x-axis). This plot 
gives a visual assessment of the different inhibitory strengths of each plant 
sample against the two enzymes, α-amylase (x-axis) and α-glucosidase (y-
axis), with three categories of inhibition strength: weak, medium and strong. 
Thus, each group represents a different combination of inhibition strength 
against α-glucosidase and α-amylase, and is divided into 9 groups (A, B, C, D, 
E, F, G, H, and I). Groups A, B and C represent categories of plant extracts 
that have strong inhibitory activity against α-glucosidase and weak, medium 
and strong inhibitory activity for α-amylase, respectively. Groups D, E and F 
are plants that showed medium inhibitory activity against α-glucosidase and 
weak to strong inhibitory activity against α-amylase respectively. Finally, 
groups G, H and I are plant extracts that exhibit low inhibitory activity against 
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α-glucosidase and weak to strong inhibitory activity against α-amylase 
respectively. A representative sample from each group will be selected and 
systematically discussed in greater depth in the following sections.  








































































 Level of inhibition activity Plants within the category 
α-glucosidase α-amylase 
A Strong Weak Nil 
B Strong Medium 25b: Dryobalanops aromatica 
C Strong Strong 49b: Mesua ferrea 
D Medium Weak 36: Garcinia mangostana; 56a: Parkia speciosa; 68a: Syzygium cumini; 11b: Baccaurea parviflora;     
17: Chrysophyllum cainito 
E Medium Medium 6b: Antidesma bunius  
F Medium Strong 45: Madhuca longifolia; 25a: Dryobalanops aromatica; 9a: Atuna racemosa 
G Weak Weak 59b: Phyllanthus pulcher; 5a: Annona muricata; 52a: Muntingia calabura; 35: Garcinia atroviridis; 
16a: Cananga odorata; 44: Lepisanthes rubiginosa; 54b: Orthosiphon aristatus; 41: Laurus nobilis; 
31a: Flacourtia inermis; 13b: Bixia orellana; 70a: Terminalia catappa; 34: Galphimia glauca; 26b: 
Etlingera elatior; 28b: Eurycoma longifolia; 71b: Ziziphus mauritiana; 14b: Butea monosperma; 5b: 
Annona muricata; 3: Alstonia angustifolia; 18a: Cinnamomum camphora; 61: Punica granatum; 50a: 
Misocarpus sundaicus; 28a: Eurycoma longifolia; 2b: Aleurites moluccana; 47: Melaleuca cajuputi; 
49a: Mesua ferrea; 50b: Misocarpus sundaicus; 52b: Muntingia calabura; 58: Phyllanthus acidus; 
26c: Etlingera elatior; 23: Cynometra ramiflora; 69b: Tamarindus indica; 66a: Synsepalum 
dulcificum; 33: Flemingia strobilifera 
H Weak Medium 24b: Dillenia indica; 15b: Calophyllum inophyllum; 38: Hamelia patens; 27: Eugenia uniflora; 10: 
Azadirachta indica; 7b: Antidesma ghaesembilla 
I Weak Strong 43: Lepisanthes alata 
 





i. Group A (Strong α-glucosidase, weak α-amylase inhibitory activity) 
Regression analysis showed that the AE of α-glucosidase and AE of α-
amylase had only a weak positive correlation (R
2
 = 0.32). As such, there are 
rarely strong α-glucosidase inhibitors with little to no inhibitory activity 
against α-amylase. In this study, there were no such plants that fit within this 
category.  
ii. Group B (Strong α-glucosidase, medium α-amylase inhibitory activity) 
49: Dryobalanops aromatica (Dipterocarpaceae) 
Dryobalanops aromatica is also commonly known as the Borneo 
camphor. This genus is apparently unique, with only a total of seven species 
that exist worldwide, most of which are confined to the tropical forests of 
Malaysia (184). Previous studies showed that this genus is a good source of 
resveratrol oligomers such as cis- and trans-diptoindonesin B (185), 
malaysianol A, laevifonol, ampelopsin, α-viniferin, -viniferin, diptoindonesin 
A and bergenin (184) Furthermore, dammarane triterpenes can also be found 
in the resin of the plant (186).  
Results in this study indicated the TPC of the stem to be about 10 
times higher (4501 ± 908 mg GAE/g plant extract) than that of the leaves (411 
 58 mg GAE/g plant extract). Similarly, the PAC of the stems was also 
significantly higher than that of the leaves, which were 2696  285 and 66  
15 mg PAE/gram plant extract respectively. The strength of inhibitory activity 
for α-glucosidase and α-amylase is quite unique in that it has relatively high 
inhibitory activity against α-glucosidase (AE = 0.44) and medium inhibitory 
activity against α-amylase (AE = 1.92). 
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iii. Group C (Strong α-glucosidase, strong α-amylase inhibitory activity) 
51: Mesua ferrea (Calophyllaceae) 
Mesua ferrea, commonly known as Ceylon ironwood, is a tree from 
the family Calophyllaceae that is indigenous to tropical Asia. In folk medicine, 
its flowers, leaves, seeds and roots have medicinal properties, and it is used to 
treat fever, dyspepsis and renal diseases (187). In addition, the lipophilic 
extract of the woody trunk of the tree seems to show significant anti-bacterial 
activity, which has sparked research interest to seek out the active compounds. 
Phytochemical investigations show the occurrence of xanthones, coumarins, 
biflavones, cyclohexanedione derivatives and essential oils (187). So far, there 
have been quite a number of xanthones isolated from the heartwood bark, such 
as a series of 4-alkyl and 4-phenyl 5, 7-dihydroxycoumarins (188),  ferruol A 
(189), mesuaxanthones (190), 1, 5-dihydroxyxanthone (II), euxanthone 7-
methyl ether (IV) and β-sitosterol (191), and ferxanthones (192). Coumarin 
derivatives have been isolated from the seeds; canophylial, canophyliol and 
canophyllic acid from the leaves.  
Results in this study show that it has one of the strongest activity 
amongst the 71 plant samples with an IC50 of 0.5 ± 0.01 µg/mL for α-amylase. 
Interestingly, the activity for α-glucosidase was a lot weaker in comparison 
(IC50 = 22.7 ± 1.8 µg/mL). Besides that, it was also shown to have the highest 
TPC (6025 ± 1120 mg GAE/g crude extract) which may be related to its high 
activity against α-amylase. The high PAC content  of  220 ± 6 mg PAE/gram 
of crude extract is likely responsible for its high activity.  
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iv. Group D (Medium α-glucosidase, weak α-amylase inhibitory activity) 
41: Garcinia mangostana (Clusiaceae) 
Garcinia mangostana, commonly known as mangosteen, is a tropical 
tree from India, Myanmar, Malaysia, Philippines, Sri Lanka and Thailand 
(193). The pericarp of the mangosteen fruit has been used medicinally in 
Southeast Asian countries and in ayurvedic medicine to treat diarrhoea, skin 
infections, wounds, amoebic dysentery and cholera (194-196). The pericarps 
were found to be rich in xanthones, which are thought to have remarkable 
biological activity. There are about fifty xanthones that have been isolated 
from the pericarp (193). For α-amylase inhibition activity, however, Loo and 
Huang (2007) found that the lipophilic xanthone, containing a fraction of the 
pericarp, did not show any activity of α-amylase, although the inhibitory 
activity of α-glucosidase was not tested. The fraction which was able to inhibit 
α-amylase significantly (IC50 = 5.2 µg/mL) was attributed to the presence of 
oligomeric PACs (197).  On the other hand, another study, which focused on 
the inhibition of α-glucosidase (pNPG assay), showed that xanthones were 
potent α-glucosidase inhibitors (IC50 = 3.2 µg/mL) (198). In addition, the 
study also showed that the ethanolic extract was able to elicit reduction of 
postprandial blood glucose levels in STZ-induced rats.  
Results in this study indicate that extracts from G.mangostana leaves 
are able to inhibit α-amylase and α-glucosidase with IC50 of 20 ± 1 µg/mL and 
57 ± 1 µg/mL respectively. TPC and PAC tests reveal high phenolic and 
proanthocyanidin contents of 783 ± 158 mg GAE/g plant extract and 237 ± 18 
mg PAE/gram sample respectively.  
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44: Syzygium cumini (Myrtaceae) 
Syzygium cumini, commonly known as jambolan, is thought to have 
originated from India or the East Indies, but has since found its way into many 
other countries like Thailand and the Philippines. In Unani and TCM, the 
leaves and bark are used to control blood pressure and gingivitis. However, the 
specialty of this plant lies in its seeds, where a decoction of the seeds, taken 
orally, is reputed to treat diabetes (199). An in vivo study isolated a compound 
called mycaminose and showed that it was able to reduce the blood glucose 
level in STZ-induced diabetic rats (200). In addition, in vitro studies have 
shown the seeds to exhibit α-glucosidase inhibition activity (8 ± 0.17 mg/mL), 
and the active compound inhibiting α-glucosidase isolated and identified as 
apigenin 7-O-glucoside (201). Several compounds like myricetin and betulinic 
acid were isolated from the seeds, and shown to be able to inhibit α-amylase in 
vitro (202).  Much attention was focused on the seeds of this plant, as 
compared to the leaves. However, the seeds were not tested in this study, as no 
seed samples were available.  
The results from this study indicated that leaf extracts were also able to 
inhibit α-amylase (IC50 = 30.9 ± 5.7 µg/mL) and α-glucosidase (IC50 = 100 ± 7 
µg/mL). TPC tests estimated phenolic contents of about 109 ± 20 mg GAE/g 
in pure plant extract. The estimated proanthocyanidin content for the leaves 
was quite low (10 ± 2 mg PAE/gram extract), suggesting that enzyme 




48: Chrysophyllum cainito (Sapotaceae) 
Chrysophyllum cainito is native to the Greater Antilles in the 
Caribbean and has since been cultivated throughout the tropics in Taiwan, 
India, Thailand, Philippines, Vietnam, Malaysia, Indonesia and Northern 
Australia. This plant is best known for its fruit, also known as the star apple 
fruit, which is nutritious and high in antioxidants. Traditionally, the ripe fruits 
are eaten to treat for inflammation caused by laryngitis, pneumonia and 
haemorrhages, or are cooked as anti-pyretics. The bark, latex and seeds also 
have medicinal uses, and are taken to stop diarrhoea, dysentery and 
haemorrhages. The plant is also taken as a remedy for diabetes, and the 
decoction of its leaf is taken orally for hyperglycaemia (203).   
Results in this study showed, for the first time, that C. cainito was able 
to inhibit α-amylase (IC50 = 29 ± 1 µg/mL) and α-glucosidase (IC50 = 26 ± 7 
µg/mL). TPC and PAC tests revealed high amounts of phenolic and 
proanthocyanidin content, which were 599 ± 74 mg GAE/g pure plant extract 
and 159 ± 28 mg PAE/gram sample respectively. It is thus reasonable to 
believe that PACs are responsible for this inhibition. 
v. Group E (Medium α-glucosidase, medium α-amylase inhibitory 
activity) 
46: Antidesma bunius (Phyllanthaceae) 
Antidesma bunius is a fruit tree that is native to Southeast Asia and 
Northern Australia. Its fruits have been used to make jam and wine (204), 
possessing a sour taste similar to that of immature cranberries. In the 
Philippines, it was reported that a concoction of its leaves is used 
ethnobotanically to manage blood sugar levels (205). The general 
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phytochemical profile of its fruit indicates that it contains flavonoids, 
phenolics and organic acids (206), and its leaves and bark contain dammara-
20, 24-dien-3β-ol, friedelin, epitaraxerol and other triterpenoids (207). 
Previous reports have shown that the leaf extracts are active against α-
glucosidase (208).  
Experimental results from this study also show that the leaves are 
active against α-amylase, with an IC50 of 2.4 ± 0.01 µg/mL, and its TPC and 
PAC were calculated to be 315 ± 35 mg GAE/g plant extract and 86 ± 9 mg 
PAE/gram sample respectively.  
vi. Group F (Medium α-glucosidase, high α-amylase inhibitory activity) 
50: Atuna racemosa (Chrysobalanaceae)  
Atuna racemosa, commonly known as merbatu, is widely available 
throughout Malesia and Oceania, spanning the Malay Peninsula to the Pacific 
Islands of Fiji, Tonga, and Samoa (209). The plant extract is reported to be 
used as an anti-inflammatory massage oil. The plant also has medicinal 
properties, and its inner, living bark may be soaked in water to make a 
concoction that is used to treat abdominal pains. Its leaves are also reported to 
have anti-inflammatory properties and are used to reduce swelling on the leg 
(209). Indeed, the kernel of the nut is shown to possess antibacterial 
properties, where its potency is dependent on the maturity of the kernel (210).  
The TPC and PAC contents of the leaves are 305  63 mg GAE/g plant 
extract and 230  36 mg PAE/g sample respectively. The plant extract 
displays higher inhibitory activity against amylase (AE = 13.49) compared to 
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that of glucosidase, which we categorised in the medium range of inhibitory 
activity (AE = 0.19). 
42: Madhuca longifolia (Sapotaceae) 
Madhuca longifolia, also widely known as the „butternut tree‟ or 
„mahua‟, is considered to be a multi-purpose forest tree, whereby it can be 
used for food, fodder or fuel. The tree can be found in tropical regions, and is 
largely located in the central and north Indian plains and forests. Its flowers 
and fruits are used as food, and is widely consumed by the tribes of western 
Odisha (211). The bark of the plant has been reported to possess anti-diabetic 
activity (212).  
TPC and PAC contents were shown to be 326  69 mg GAE/g plant 
extract and 99  16 mg PAE/gram sample respectively. Our results also 
indicate that the extracts are active against α-amylase with an IC50 and AE of 
0.9  1.0 µg/mL and 3.94 respectively. For α-glucosidase, the IC50 and AE 
values were 17.1  0.8 µg/mL and 0.15 respectively.  
vii. Group G (Weak α-glucosidase, weak α-amylase inhibitory activity) 
33: Synsepalum dulcificum (Sapotaceae) 
Synsepalum dulcificum is an evergreen shrub that is native to the 
western tropics and west central Africa. It has been introduced into many 
Southeast Asian countries, Australia, and in the United States. Its red berries 
contain an interesting glycoprotein called miraculin, which is tasteless on its 
own, but remarkably able to modify a sour taste into a sweet taste. Studies 
have also reported that miraculin can reduce insulin resistance in rats (213). In 
the stems, there were a number of compounds isolated, namely: dihydro-
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feruloyl-5-methoxytyramine, (+)-syringaresinol, (+)-epi-syringaresinol, 4-
acetonyl-3, 5-dimethoxy-p-quinol, cis-p-coumaric acid, trans-p-coumaric acid, 
p–hydroxybenzoic acid, syringic acid, vanillic acid, veratric acid, N-cis-
feruloyltyramine, N-trans-feruloyltyramine and N-cis-caffeoyl tyramine (214). 
For the leaves, eight compounds were reported to be isolated, namely: 
sitosterol and stigmasterol, pheophytin-a, pheophytin-b, lupeol, lupenone, 
lupeol acetate, and tocopheryl quinone (215).  
This work is the first of its kind to study the inhibitory activity of this 
species against α-amylase and α-glucosidase. The IC50 values of the leaf 
extract for α-amylase and α-glucosidase are 22.0 ± 18.0 and 37.9 ± 3.6 µg/mL 
respectively. 
32: Tamarindus indica (Leguminosae) 
Tamarindus indica, popularly known as tamarind, is an important 
multi-purpose tropical fruit tree originating from the Indian subcontinent. It is 
widely used as traditional medicine in India, Africa, Pakistan, Nigeria and 
most tropical countries. Although a lot of research focuses on the fruit pulp of 
this tree, every part of the plant, from the root to the leaf, may be beneficial for 
human needs. Traditionally, it has been used to treat many ailments including 
abdominal pain, diarrhoea, wounds, malaria, fever, constipation and eye 
diseases. It is also rich in phytochemicals and is reported to possess anti-
microbial, anti-malarial, hepatoprotective, anti-asthmatic, laxative, anti-
hyperlipidemic and anti-diabetic effects (199, 216). For anti-diabetic 
properties, several in vivo experiments have indicated that the aqueous extract 
of the leaves and seed of T.indica, when fed to diabetic wistar rats, lowered 
blood glucose levels to normal in a glucose tolerance test (217-219). In vitro 
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studies also showed that the extract of the leaves led to an α-amylase 
inhibition of 90 % (220).  
Similarly, results in this study indicated that the stems of the plant 
inhibited α-amylase with an IC50 of 4.4 ± 1.0 µg/mL and α-glucosidase with 
an IC50 of 30.2 ± 12.7 µg/mL. TPC and PAC tests revealed relatively high 
amounts of phenolic and proanthocyanidin content of 413 ± 70 mg GAE/g 
plant extract and 201 ± 17 mg PAE/g respectively.  
8: Laurus nobilis (Lauraceae) 
Laurus nobilis originated from tropical southern Asia, and is now 
distributed in the West Indies, South and Central America, the Mediterranean 
region and in Africa. Traditionally, it has a variety of medicinal uses. It can be 
taken orally as a carminative, tranquilizer, to improve circulation, 
antispasmodic for abdominal colic, to induce menstruation and as an 
emmenagogue. Externally, it may be applied as an anti-rheumatic, and to 
soften tumours and ulcers. Some of its reported pharmacological activities are 
its anti-bacterial, anti-hypertensive, anti-inflammatory, anti-fungal and 
hypoglycaemic effects, among several others (199). A study found that the 
consumption of 1-3 g/day of L.nobilis for 30 days was able to decrease the risk 
factors for diabetes and cardiovascular diseases (221). Several in vitro studies 
have shown the essential oil obtained from L.nobilis to be potent inhibitors of 
α-amylase and α-glucosidase (222, 223).  
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viii. Group H (Weak α-glucosidase, medium α-amylase inhibitory 
activity) 
38: Azadirachta indica (Meliaceae) 
Azadirachta indica, famously known as the „neem tree‟, is used in 
ayurvedic medicine for treating diabetes mellitus and peptic ulcers. Due to its 
medicinal properties, this plant has been extensively studied over the past, 
which has led to the isolation and characterization of more than 135 
compounds (224). In vivo studies showed that the seed oil and leaf extracts are 
able to lower blood glucose in diabetic animals (225, 226). The active 
compounds that are thought to be responsible for its hypoglycaemic effect 
comes from tetranortriterpenoids called meliacinolin (227).  
Results in this study show that A. indica inhibited α-amylase (IC50 = 17 
± 1 µg/mL) and α-glucosidase (IC50 = 73 ± 7 µg/mL). TPC and PAC tests 
revealed relatively high amounts of phenolic and proanthocyanidin content of 
189 ± 27 mg GAE/g crude extract and 35 ± 5 mg PAE/gram sample 
respectively. 
39: Antidesma ghaesembilla (Phyllanthaceae) 
Antidesma ghaesembilla is a wild, edible, dioecious plant and its leaves 
have been used by the tribal people of the Western Ghats as medicine for 
headaches. Its stem is used to stimulate menstrual flow, and the fruit used as a 
purgative (228).  
Experimental results from this study show that the leaves and stem 
both have strong inhibitory activity against α-amylase, with IC50 values of 1.4 
± 0.01 and 2 ± 0.01 µg/mL respectively. Their activity against α-glucosidase, 
however, was much lower compared to α-amylase (IC50 = 17.6 ± 7.9 µg/mL). 
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The TPC for the stem and leaves were estimated to be about 186 ± 23 and 360 
± 65 mg GAE/g plant extract respectively. For the proanthocyanidin content, 
the leaves have much lower levels of proanthocyanidins (48 ± 7 mg PAE/gram 
plant extract) as compared to the stems (171 ± 27 mg PAE/gram plant extract).  
ix. Group I (Weak α-glucosidase, strong α-amylase inhibitory activity) 
40: Lepisanthes alata (Sapindaceae) 
Lepisanthes alata is a small tree of about 4-5 m tall originating from 
the Sapindaceae family. The aril of the fruits can be eaten when it has ripened, 
and the young leaves are usually cooked and eaten as vegetables in southern 
Thailand (229). Results in this study indicate that the leaves possess relatively 
strong inhibitory activity against α-amylase (IC50 = 7 ± 0.01 µg/mL) and α-




Table 2. The total phenolic content, proanthocyanidins content, IC50 & acarbose equivalent of α-amylase & α-glucosidase of plant extracts 
collected from the Singapore Botanic Gardens. 
No. Latin Name Common names Plant 
part 




























tutui, candlenut; nuez, 
nuez de India (Puerto 
Rico);lumbang (Guam); 
Sakan (Palau); lama (Am. 
Samoa), Candlenut Tree, 








stem Medicinal 91  7 39  4 5.0  2.0 0.61 73  11 0.05 













Cashew Nut; Gajus; 
Cashew; Janggus; Jambu 
Gajus; Jambu Golok; 
Keterek; Terek; Jambu 
Bongkok; Jagus 
leaf Medicinal 299  74 162  30 - - 32  4 0.11 





soursop, prickly custard 
apple, Soursapi 
leaf Edible 195  19 75  9 401  267 0.00 181  112 0.01 
stem Edible 313  49 - 620  183 0 332  59 0.03 
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No. Latin Name Common names Plant 
part 























Its common Philippine 
name and other names 
include bignay, bugnay or 
bignai, Chinese-
laurel,Herbert  










Sekinchak, Black Currant 
Tree; Gunchak; Gunchek; 
Guchek; Gunchian; 
Gunchin 
leaf Edible 186  23 48  7 2.0 1.60 - - 
stem Edible 360  65 171  27 1.4  0.0 2.29 18  8 0.13 
8 Ardisia elliptica 
Seashore Ardisia; Mata 
Pelanduk; Penah; Periah; 
Buah Letus; Cempenai; 
Daun Bisa Hati; Mata 
Ayam; Mata Itek; Mata 
Pelandok; Mempenai; 
Rempenai 
leaf Medicinal 271  11 88  7 - - 14  2 0.21 
9 Atuna racemosa Merbatu 
leaf Medicinal 305  63 230  36 1.4  0.4 13.49 0.9  4.0 0.19 
stem Medicinal 378  37 213  24 - - 11  1 0.25 
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No. Latin Name Common names Plant 
part 























The English name neem is 
borrowed from Hindi. The 
Urdu, Arabic, and Nepali 
names are the same. Other 
vernacular names include 
Nimm in Sindhi and 
Punjabi, Nim in Bengali, 
Vembu (Tamil), Arya 
Veppu (Malayalam), 
Azad Dirakht (Persian), 
Nimba, Arishta, 
Picumarda (Sanskrit, 
Oriya), Limdo (Gujarati 
language) Kadu-Limba 
(Marathi), Dogonyaro (in 
some Nigerian languages 
-- Hausa), Margosa, 
Nimtree, Vepu, Vempu, 
Vepa (Telugu), Bevu 
(Kannada), Kodu nimb 
(Konkani),(Kohomba, 
Sinhala), Tamar 
(Burmese), sầu đâu, xoan 
Ấn Độ (Vietnamese), 
(Sdao, Khmer), สะเดา 








language) and Paraiso 
(Spanish). In East Africa 
it is also known as 
Muarubaini (Swahili), 
sisibi (in some Ghanaian 
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No. Latin Name Common names Plant 
part 

























Wild Rambai; Rambai 
Hutan 





stem Edible 248  15 2  0.3 374 0.01 - - 
leaf Edible 289  56 6  1 65 0.04 - - 
13 Bixia orellana 
Lipstick Plant; Achiote; 
Anatto; Kesumba; Jarak 
Belanda; Annato Dye 
Plant; Kunyit Jawa; 
Kesumba Keling 
stem Medicinal 177  31 116  11 69  20 0.03 200  42 0.02 




Flame of the Forest; 


























Kenanga; Ilang Ilang; 
Ylang Ylang; Kenanga 
Hutan; Perfume Tree; 
Cananga; Kenanga Utan; 
Chenanga; Nyai ; Nerian 
leaf Medicinal 71  7 6  0.8 117  83 0.05 899  378 0.01 
stem Medicinal 85  8 16  3 174  88 0.03 - - 
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No. Latin Name Common names Plant 
part 























Cainito, caimito, star 
apple, golden leaf tree, 
abiaba, pomme du lait, 
estrella, milk fruit and 
aguay. It is also known by 
the synonym Achras 
cainito. In Vietnam, it is 








Camphor Tree; Japanese 
Camphor Tree 




























Medicinal 395  135 217  19 16  4 0.50 103  68 0.07 
24 Dillenia indica 
Elephant apple, 
Chulta/Chalta or Ouu 





Camphor Tree, Malay 
Camphor, or Sumatran 
Camphor, 
leaf Medicinal 411  58 66  15 2.8 3.75 32  5 0.25 




Torch Ginger, Ginger 
Flower, Red Ginger Lily, 
Torch Lily, Wild Ginger, 
flower Edible 170  9 102  10 70  10 0.46 129  12 0.07 
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No. Latin Name Common names Plant 
part 





















Kantan, Philippine Wax 
Flower, Xiang Bao Jiaing, 
Indonesian Tall Ginger, 
Boca de Dragón, Rose de 
Porcelaine, Porcelain 
Rose 




Pitanga, Surinam Cherry, 










stem Medicinal 194  32 130  18 149  162 0.13 117  96 0.02 




Weeping fig, Benjamin's 






108  15 35  5 - - - - 
30 Ficus deltoidea Mistletoe fig, mas cotek 
flower Medicinal 8944  863 216  30 - - - - 
leaf Medicinal 242  29 403  16 - - - - 





Lovi-lovi, or batoko plum 
stem - 97  9 23  1.5 - - 35.0  5.5 0.08 













Medicinal 205  17 152  21 11  2 0.36 57  8 0.09 
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No. Latin Name Common names Plant 
part 

















































Heaven lotus leaf 
Non-
edible 
3320  663 78  16 - - 7.4  1.6 0.34 
38 Hamelia patens 
Firebush, Hummingbird 









Confederate rose or 
the cotton rosemallow 




Rose mallow, Chinese 
hibiscus, China 
rose and shoe flower, 
stem Edible 95  21 
- 
 




True Laurel; Bay Laurel; 




Edible 136  34 42  7 35  0.0 0.09 356  158 0.01 



















Edible 156  40 52  9.6 32.0  4.2 0.06 127.5  6.4 0.01 
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No. Latin Name Common names Plant 
part 























Mowra Butter Tree; 








Manioc, yuca, balinghoy, 
mogo, mandioca, 
kamoteng kahoy, and 
manioc root, 




Cambodia : smach 
chanlos; Danish : punk 
tree; (Filipino) : swamp 
tea-tree; (Indonesian) : 
galam (Sundanese); 
Malay) : gelam; (Thai) : 
samet-khao; Vietnamese) 
: c[aa]y tr[af]m; paper-











Senduduk leaf Medicinal 627  66 14  2.3 - - 132  13 0.06 
49 Mesua ferrea 
Ceylon ironwood, Indian 
rose chestnut, or Cobra's 
saffron), 
leaf Medicinal 310  58 193  35 6.0  2.0 0.38 56  13 0.06 





leaf Medicinal 352  78 110  30 13  3 0.26 57  8 0.05 








Medicinal 50  10 1  0.2 2760  1315 0.01 - - 
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No. Latin Name Common names Plant 
part 























Amaican cherry, Panama 
berry,Singapore 
cherry, Bajelly 
tree, Strawberry tree; 
(Spanish) bolaina, yaman
aza,cacaniqua, capulín 
blanco, nigua, niguito, me
mizo or memiso; 
(Indonesia) kersen,talok; 
(Vietnamese) Trứng cá 
(thực vật); and 
(Filipino) alatris, aratilis, 
manzanitas andsarisa. 
stem Edible 358  42 115  13 408  313 0.02 931  26 0.07 








umis kucing (Indonesia)  
misai kucing (Malaysia).  
US- it may be commonly 
known as Cat's Whiskers 
or Java tea. 
leaf Edible 234  48 13  2 121  12 0.03 - - 




Malabar chestnut, Guiana 
chestnut, provision tree, 
saba nut, monguba 
(Brazil), pumpo 
(Guatemala) and is 
commercially sold under 
the names money tree and 
money plant. 
stem Edible 39  6 1  0.2 - - - - 
leaf Edible 160  34 48  5 3.6  0.0 0.93 - - 
56 Parkia speciosa Petai; Nyiring; Nitta Tree leaf Medicinal 27  3 13  2 15.9  0.8 0.26 129  159 0.16 
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No. Latin Name Common names Plant 
part 


































country gooseberry, star 
gooseberry, West India 
gooseberry, damsel, 
grosella (in Puerto Rico), 
karamay (in the 









Kelurut tanjong, naga 
buana, semelit patong 
(Malaysia) 
leaf Medicinal 30  4 7  1.4 - - - - 













Medicinal 546  82 2  0.5 24.0 0.44 183  36 0.04 
















Khee tai, phae, ya waeng 
(Thailand); Silverback; 
leaf Medicinal 490  89 138  21 - - 20.5  2.1 0.41 
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No. Latin Name Common names Plant 
part 

























Downy rose myrtle, 
downy myrtle, hill 




Medicinal 6809  416 146  9 - - - - 








Borneo: Aeba, Jambu 
hutan, Obah 










jambolan, black plum, 
Damson plum, Duhat 
plum, Jambolan plum or 
Portuguese plum. Malabar 
plum may also refer to 
other species of 
Syzygium. This fruit is 
called Neredu Pandu in 
Telugu, Naaval Pazham in 
Tamil, Njaval Pazham in 
leaf Edible 109  20 10  2 31  6 1.18 100  7 0.16 
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No. Latin Name Common names Plant 
part 




















Malayalam, Nerale Hannu 
in Kannada, Jam in 
Bengali, Jamukoli in 
Oriya and Jambu in 
Gujarat. In the 
Philippines, common 
names include duhat in 
the Tagalog-speaking 
regions, lomboy in the 
Cebuano-speaking areas 
and inobog in 
Maguindanao. It is called 
Dhanbu in Maldives and 
Dhuwet/Juwet in 
Javanese. Among its 
names in Portuguese are 




and guapê, always with 
lower case, the early four 
derived from the Konkani 
name jambulan.They are 
called rotra in the 
Malagasy language 
(Madagascar) 
stem Medicinal 438  76 73  7 - - - - 
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No. Latin Name Common names Plant 
part 























Tamarind in Indonesia 
and Malaysia, tamarind is 
known as the asam (or 
asem) Jawa (means 
Javanese asam), In the 
Philippines, tamarind is 
referred to as sampaloc, 
which is occasionally 
rendered as sambalog in 
Tagalog and sambag in 
Cebuano. The Vietnamese 
term is me. In Taiwan, it 
is called loan-tz. In 
Myanmar, it is called 
magee-bin (tree) and 
magee-thee (fruit). The 
tamarind is the provincial 
tree of the Phetchabun 
province of Thailand, 
where it is called má 
kăam (มะขาม). In Laos, it is 
called ໝາກຂາມ (maak-
kham). In Malagasy, it is 
called voamadilo and kily. 
leaf Edible 237  77 99  17 - - 71  9 0.02 




榄仁树, Sea Almond; 
Ketapang; Indian 
Almond; Tropical 
stem Medicinal 86  7 2  0.3 - - - - 
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No. Latin Name Common names Plant 
part 




















Almond Tree; Lingtak; 
Bastard Almond; 
Singapore Almond; 
Telisai; Jelawai Ketapang; 
Pacific Almond 





Apple, Jujube, Indian 
plum and Masau 
leaf Edible 281  57 118  22 20.3 - 87  28 0.02 
stem Edible 259  39 119  19 22  4 0.16 112  66 0.02 
a TPC ± SD is the mean total phenolic content and its standard deviation measured from three readings of the plant extract.  
Data is expressed as milligrams of gallic acid equivalent per gram of plant extract (mg GAE/ g plant extract).  
b PAC ± SD is the mean proanthocyanidin content and the standard deviation taken from three readings of the plant extract. 
Data is expressed as milligrams of procyanidin A2 equivalent per gram of plant extract (mg PAC/ g plant extract). 
c IC50 is the concentration of plant extract which inhibits 50 % of α-amylase / α-glucosidase. Data is expressed as micrograms per millilitres ± standard deviation (µg/mL ± 
SD). 
d AE is the acarbose equivalent of α-amylase / α-glucosidase. 
e Botanicals labelled as “edible” are eaten as everyday foods (e.g. vegetables) whereas plants labelled under “medicinal” are taken occasionally to treat certain ailments.  
Hyphens signify tests not carried out and that the data is not available.   
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4.3.1 Correlation studies  
In order to assess if a particular group of compounds (i.e. 
proanthocyanidins and polyphenols) contributed significantly to the inhibitory 
activities of starch hydrolases, two correlation studies were carried out. The 
first set of correlation studies was between the proanthocyanidin contents, 
estimated using the DMAC assay, with the AE of α-amylase and α-
glucosidase. Figure 22 A and B show the PAC-AE correlation of both 
amylase and α-glucosidase to be weak, with R2 values of 0.1 and 0.32 
respectively. The second set of correlation studies was between the TPC and 
AE of α-amylase and α-glucosidase. Our results show that TPC had a weak to 
no correlation with the AE of α-amylase (R2 = 0.0214) and α-glucosidase (R2 
= 0.1889) (Figure 22 B and C).  
Overall, PAC contents had higher correlation with the inhibition of 
starch hydrolases. As such, our results suggest that proanthocyanidins 
contribute more towards the inhibition of starch hydrolases as compared to 
phenolic contents. The reasons contributing to the lack of correlation observed 
between PAC and TPC contents, with the inhibitory strength of starch 
hydrolases, suggests that starch inhibitory activity is not caused exclusively by 
a specific group of compounds, but possibly through interactions occurring 
between different groups of compounds, which could give a cumulative 
inhibitory effect. Additionally, the presence of specific compounds, with 
potent inhibitory activity, may be present. Contrary to the lack of correlation 
observed with TPC-enzyme inhibition and PAC-enzyme inhibition, the mean 
TPC and PAC was shown to possess relatively strong positive correlation 
(Figure 23) with each other (R
2
 = 0.65), which is expected, since procyanidins 
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are phenolic oligomers that are mainly composed of (+)-catechin and (-)-
epicatechin.  
 
Figure 22. Correlation of (A) PACs and AE (α-amylase), (B) PACs and AE (α-
glucosidase), (C) TPC and AE (α-amylase) and (D), TPC and AE (α-glucosidase). 
 




































Mean TPC  (mg GAE/g plant extract)
y = 0.3104x - 5.4305
R² = 0.65
 
Figure 23. Correlation between the mean TPC and PACs values. 
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In summary, we have shown that the turbidity assay is an effective 
high-throughput methodology for the evaluation of starch hydrolase inhibition, 
in screening botanical materials. Furthermore, some of the selected botanicals 
show great potential as a source of novel inhibitors, and lay the groundwork 
for future in-depth studies of isolation and characterization of pure inhibitors 
from botanicals.  It should also be noted that this study is based on in vitro 
methodologies. Since in vitro methods are over-simplistic, further in vivo 
studies, which are more complicated but more representative of the human 

















Characterization of proanthocyanidins from 
torch ginger flower (Etlingera elatior) as strong 
starch hydrolase inhibitors  
5.1 Introduction  
Etlingera elatior is a flower which is also known by many different 
common names as torch ginger, ginger flower, red ginger lily, torch lily, wild 
ginger, combrang, bunga kantan, philippine wax flower, xiang bao jiang, 
indonesian tall ginger, boca de dragón, rose de porcelain and porcelain rose 
(230). The flower is used as an ingredient in many Southeast Asian cuisines. 
For example, the flower buds are used as important ingredients in the nonya 
laksa dish as well as in „rojak‟ (231). In North Sumatra, the buds are used for a 
dish called „arsik ikan mas‟ and in Thailand, it is ingredient of Thai salad. In 
East Malaysia, the young shoots are consumed by indigenous communities as 
a condiment, eaten raw or cooked as a vegetable (232). Some of the traditional 
uses/effects of this flower include its use in reducing the odour of fish and in 
the inhibition of pathogenic bacteria and moulds on food (233). In Malaysia, 
the fruits of E. elatior may be applied as a remedy for earache and its leaves 
for cleaning wounds (234).  
Based on the available literature, the main flavonoids that have been 
identified in the leaves of E. elatior are kaempferol-3-glucuronide, quercetin-
3-glucuronide, quercetin-3-glucoside, and quercetin-3-rhamnoside (235). 
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Quantitatively, the dry weight of the flower has been estimated to be about 
286 mg/ kg (236). The quantitative amount of quercetin in the extracts of E. 
elatior as determined by HPLC analysis was 1.18 ± 0.06 mg/ 100 mg (233). 
3-O-caffeoylquinic acid, 5-O-caffeoylquinic acid (chlorogenic acid), 
and 5-O-caffeoylquinic acid methyl ester were isolated from the leaves of 
E.elatior (237). The leaves were also shown to be non-toxic to normal liver 
and kidney cells.  In vivo brine shrimp lethality tests also showed that the 
methanolic extract of the flower exhibited a very high LC50 value, which 
signifies that this plant is not toxic to humans (238). Two new compounds and 
six known compounds of diarylheptanoids, labdane diterpenoids and steroids 
were isolated, namely 1, 7-bis(4-hydroxyphenyl)-2,4,6-heptatrienone (1), 
demethoxycurcumin (2), 1, 7-bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one 
(3), 16-hydroxylabda-8 (17), 11,13-trien-16,15-olide (4), stigmast-4-en-3-one 
(5), stigmast-4-ene-3, 6-dione (6), stigmast-4-en-6b-ol-3-one (7), 5α, 8α-
epidioxyergosta-6,22-dien-3β-ol (8). Compounds 5 and 7 were shown to have 
high anti-tumour activity (239).  
The E. elatior extract was shown to be able to protect bone marrow 
from the damaging effects of lead toxicity and it is suggested that it can be 
used as a therapeutic agent against chronic lead intoxication in combination 
with lead chelating agents (240, 241). Leaves of the E.elatior displayed high 
tyrosinase inhibition activity, which has implications in application in foods 
and cosmetics, as neither hyperpigmentation in human skin nor enzymatic 
browning in fruits are desirable (242). The ethanolic extracts of E. elatior have 
antimicrobial activity and are cytotoxic to HeLa cells (243). 
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As such, current literature strongly suggests that extracts from E. 
elatior are of medicinal value. However, this is the first time the anti-diabetic 
effect of its α-amylase inhibition activity has been carried out in depth. 
Reported herein are the results of my attempts to elucidate the active 
compounds in the inflorescence of E. elatior. More specifically, by applying a 
high throughput assay, I successfully identified PACs in the flower extract as 
potent α-amylase inhibitors. In addition, polyphenolic profiles of several 
active fractions that may have contributed to its inhibition activity were 
studied. This work shows that E. elatior possesses potent inhibitors which may 
serve as functional ingredients in reducing PPHG.   
5.2 Materials and methods 
5.2.1 Reagents and instruments 
The reagents were purchased from commercial sources: Folin & 
Ciocalteu‟s phenol reagent (Merck, Darmstadt, Germany), sodium carbonate 
(Sigma, cat. no. S7795), and gallic acid (Sigma, cat. no. 48630). 
5.2.2. Extraction and purification of proanthocyanidins from Etlingera 
elatior inflorescence 
E.elatior (5 kilograms) was sampled from the Singapore Botanic 
Gardens or purchased from the Pasir Panjang wholesale market in Singapore. 
The flowers were washed thoroughly and blot dried to remove any traces of 
possible impurity or potential pesticide contamination. The inflorescences 
were then frozen in a - 20 ºC freezer, freeze dried and subsequently grounded 
to powder. The resulting powder was extracted with methanol at a ratio of 
1:10 (w/v) powder to solvent with shaking for 24 hours at room temperature.  
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The initial methanolic crude extract, after washing with a variety of 
immiscible solvents with different polarities, was concentrated. The 
concentrated methanolic extract was diluted to obtain a 95 % aqueous 
methanolic solution. The extract was “defatted” with an equal volume of n-
hexane three times. Two distinct layers were collected using a separation 
funnel and the methanolic layer was evaporated to dryness and re-dissolved in 
water. The solution then underwent successive partitioning of chloroform 








5.2.3 Sephadex LH-20 fractionation of butanol and aqueous extract 
Butanol extract (0.5 g dissolved in methanol) was loaded on to the 
Sephadex LH-20. The column was eluted using a linear elution gradient of 
increasing percentage of methanol-water (0, 20, 40, 60, 80, 100 % v/v), and 
100 mL of eluent was collected for each gradient.  
5.2.4 Characterization of proanthocyanidins in E. elatior 
Ten milligrams per millilitre of aqueous (in water), butanol (in water) 
and ethyl acetate (in methanol) fractions were filtered through an RC 0.45 µm 
membrane filter before 20 µL was injected for HPLC analysis (250 x 4.6 mm 
i.d., 5 µm, Develosil diol with a 4 x 4 mm i.d. guard column of the same 
materials. The materials came from Seto, Japan). The elution conditions were 
as follows: flow rate of 1.0 mL/min; column temperature of 35 °C; mobile 
phase A of 2 % acetic acid in acetonitrile; mobile phase B of acidic aqueous 
methanol (CH3OH: H2O: HOAc, 95:3:2 v/v/v). The first mobile phase 
condition was 7 % of B held isocratic for 3 minutes, before ramping solvent B 
to 37.6 % over 57 minutes, and then to 100 % of B for 3 minutes thereafter. B 
was held at 100 % for 7 minutes prior to returning to the starting condition (7 
% of B) in 6 minutes. The column was equilibrated with 7 % of B for 5 
minutes prior to the next run. The electrospray ionization mass spectra were 
recorded from a Finnigan/MAT LCQ ion trap mass spectrometer (San Jose, 
CA) equipped with a TSP 4000 high-performance liquid chromatography 
(HPLC) system, which included an UV6000LP photodiode array detector (set 
at 280 nm), P4000 quaternary pump and AS3000 autosampler, at a set column 
temperature of 35 ºC. The heated capillary and voltage were maintained at 250 
C and 4.5 KV respectively. Nitrogen was operated at 80 psi for the sheath gas 
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flow rate and 20 psi for the auxiliary gas flow rate. The full scan mass spectra 
from m/z from 50-500 were acquired in both positive and negative ion modes 
with a scan speed of 1 s/scan. 
5.2.5 Determination of α-amylase inhibition activity of E. elatior 
fractions 
The inhibition activity was determined using a method that was 
established previously (175). The method was described in detail in section 
4.2.5. 
5.2.6 Determination of Total phenolic contents 
The TPC method was described in detail in section 4.2.3. 
5.2.7 Determination of Proanthocyanidin content 
The DMAC method was described in section 4.2.4. 
5.3 Results and discussion 
5.3.1 Determination of TPC and PAC of E. elatior extract 
The TPC of the butanol extract of E. elatior was determined using the 
Folin-Ciocalteu method. The result was a 371.1 ± 48.0 mg GAE/g extract. The 
proanthocyanidin content of a crude extract of the E. elatior flower was a 
754.7 ± 113.1 µg PAE/g extract. 
5.3.2 α-Amylase inhibition activity of E. elatior fractions 
Figure 25 shows the kinetics of change in the optical density of 
inhibitors present in the various fractions against α-amylase and the AUC, 
which translates to the dose response curves as shown in the insets. Figure 25 
A, B, C and D show the inhibitory activity for aqueous, ethyl acetate, butanol 
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and acarbose respectively and the IC50 of the various fractions are shown in 
Table 3. The aqueous extract was the most potent fraction as compared to the 
other crude fractions, with an IC50 of 13 ± 3 µg/mL. The potency of the 
aqueous extract was still less active as compared to acarbose (IC50 = 8 ± 2 
µg/mL). Following this, the butanol fraction was the next most active fraction 
(IC50 = 89 ± 14 µg/mL). Further purification of the butanol fraction (fraction 
G) via Sephadex LH-20, which was washed with 100 % methanol, resulted in 
an increase in the potency of the butanol fraction (IC50 = 37 ± 5 µg/mL). 
Finally, the ethyl acetate fraction had little activity (IC50 = 321 ± 12 µg/mL) 




Figure 25. Change in optical density measured at 660 nm at various concentrations of 
E. elatior fractions (A) acarbose, (B) aqueous, (C) butanol, (D) LH-20 fraction G 
from butanol and (E) Ethyl acetate. Insets show the dose-response curve. 
 
Table 3. The IC50 of α-amylase inhibition activity of various fractions. 
Fractions IC50 (µg/mL) 
Acarbose 8 ± 2 
Aqueous  13 ± 3 
Butanol 88.6 ± 14 
LH-20 Fraction G from BuOH 100% MeOH 37 ± 5 
Ethyl acetate  321 ± 12 
Hexane No inhibition 
Chloroform No inhibition 
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5.3.3 Proanthocyanidin identification of active crude extracts from E. 
elatior inflorescence 
The E. elatior PACs were separated and analysed by a Develosil diol 
HPLC column that gave chromatographic separations based on the degree of 
polymerisation (or molecular weight), which was determined by the ESI-MS
n
 
negative mode to obtain the distribution of different oligomers. Figures 26 A, 
B and C show the HPLC chromatograms of PACs from different fractions (i.e. 
aqueous, butanol and ethyl acetate). Identification of OPCs was based on their 
mass spectra as well as a comparison of their retention times to previously 
published reports. Their molecular weights and fragment ions are summarised 
in Table 4. Peak 3 gave the m/z value of 866 [290 x 3 - (3-1) x 2]. Its cationic 
MS
2
 gave daughter ion peaks at m/z 695, 577, 406 and 286, indicating a 
procyanidin skeleton composed of three (epi)catechin moieties. Peak 4 has a 
m/z of 1154 [290 x 4 – (4-1) x 2]. Its main cationic MS2 fragments gave peaks 
at m/z 867 and 579. Hence, its main fragment ions are at m/z 287 and 575, 
which are common fragments from interflavanoid bond cleavage. A mass of 
m/z 287 was a quinone methide (epi)catechin, which indicated that 




Figure 26. HPLC chromatograms of proanthocyanidin profiles from (A) aqueous, (B) 
































































5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 60.00 65.00 70.00 75.00 80.00
(A) Aqueous 
(B) Butanol 




















MW MS (m/z) MS
2
 ions (m/z) Tentative 
compound 
assignments 












Trimer (B type) 









 , 1135, 



































Peak 5 has a m/z of 1442 [290 x 5 – (5-1) x 2] and peak 6 has a m/z of 
1730 [290 x 6 – (6-1) x 2], which can be identified as pentamers and hexamers 
with (epi)catechin B type linkage, respectively.  
In order to quantify the different oligomeric procyanidins, of different 
degrees of polymerisation from the various fractions, pure standards are 
required. Nevertheless, an estimation of the quantity of procyanidins can be 
carried out by an integration of the area under the curve of the peaks. Figures 
26 A and B show that the aqueous and butanol fractions contain more 
procyanidins that are of a higher degree of polymerization (DP > 7) as 
compared to the ethyl acetate fraction (Figure 26 C). Previous studies showed 
that higher procyanidin oligomers exhibit stronger inhibitory activity as 
compared to polyphenolic monomers (244). Similarly, our results also indicate 
that ethyl acetate, with low amounts of higher procyanidin oligomers, has 
lower inhibitory activity (IC50 = 321 ± 12 µg/mL) compared to the butanol 
(IC50 = 88.6 ± 14 µg/mL) and aqueous (IC50 = 13 ± 3 µg/mL) fractions, which 
contain higher amounts of polymeric oligomers.   
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5.3.4 Determination of α-amylase inhibition activity of fractions of 
butanol extract with Sephadex LH-20 
Purification and fractionation of the butanol extract with Sephadex 
LH-20, with increasing percentage of methanol/water, generated 0, 20, 40, 60, 
80 and 100 % methanolic fractions, which are named as fraction 1, 2, 3, 4, 5 
and 6 respectively. Fraction 1 did not show any inhibitory activity, and direct 
injection on the mass spectrometer suggests that high amounts of chlorogenic 
acid are present in the 100 % water fraction. Fraction 2 (20 % methanol) gave 
slight inhibitory activity (IC50 = 2.85 mg/mL), whereas fraction 3 (40 % 
methanol) and 4 (60 % methanol) had no activity at all. The last two fractions, 
5 (80 % methanol) and 6 (100 % methanol), had relatively high α-amylase 
inhibition, with IC50 of 0.861 and 0.037 mg/mL respectively. Direct injection 
of fraction 5 revealed a predominant mass ion with a m/z value of 464, which 
could potentially be identified as isoquercitrin, since E. elatior has been 
reported to be rich in quercetin derivatives (235). Direct mass injection of 
fraction 6 reveals predominant m/z values of 1153, 865, 576 and 354, which 
indicates that this fraction could be enriched with proanthocyanidins.  
5.3.5 Fractionation of aqueous extract with Sephadex LH-20 
Fractionation via the Sephadex LH-20 was also carried out with the 
aqueous extract, since it had the highest inhibitory activity with the same 
gradient run of methanol/water (0, 20, 40, 60, 80 and 100 %) as was done with 
the butanol extract. The LH-20 fractions will be designated as fractions 7, 8, 9, 
10, 11 and 12 respectively, from the lowest methanol percentage to the 
highest. Fractions 7, 8 and 9 showed little or no activity, and direct mass 
injection of fraction 7 showed high contents of chlorogenic acids. α-amylase 
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inhibitory activity was progressively stronger from fractions 10 to 12, with 
fraction 12 being the most active. Direct mass injection of fractions 11 and 12 
indicated similar mass profiles, whereas fraction 10 was different. As such, 
further analyses of fractions 10 and 12, using a LC-MS
n
 with a C18 column, 
were done to separate and identify potential inhibitors.  
5.3.6 Identification of compounds in fraction 10 by LC-MS
n
  
The HPLC chromatogram of fraction 10 is shown in Figure 27. 
Identification of the peaks obtained by LC-MS is summarised in Table 5. 
Peak 1 had [M+H]
– 
at m/z 449, with a fragment at m/z 287 (loss 162 due to 
potential amu: hexose moiety), and was identified as kaempferol-3-O-
glucoside (245). Peak 2 had a [M+H]
+  
ion at m/z 579, with fragment ions at 
m/z 427, 409 and 291, which indicated that it was a dimer of procyanidin B1 
(246). Peak 3 had a [M+H]
+
 ion at m/z 290 with a fragment ion at 273 (loss of 
18 due to potential amu; water), which is likely to be an epi (catechin) moiety. 
Peak 4 had a [M+H]
+
 ion at m/z 627, daughter ions at m/z 465, 303 at ESI-
MS
2
, and a sequential loss of 303 by ESI-MS
3
 respectively, which indicates a 
quercetin–hexose–hexose structure of C27H30O17. Hence, this peak was 
assigned to be quercetin-3,4'-O-di-β-glucopyranoside (247). Peak 5 was 
assigned as chlorogenic acid with [M+H] at m/z 355, with a MS
2
 of m/z 162 
(caffeic acid) and m/z 174 (for the fragment of 
trihydroxycyclohexanecarboxylic acid). MS
3
 also gave a fragment m/z of 144 
(loss of water molecule) (248). Peak 6 showed a mass [M-H] at m/z 521 with a 
fragment mass of m/z 270 (from the glucoside moiety) which may tentatively 
be identified as diconiferyl alcohol glucoside. Peak 7 had a mass [M+H] at m/z 
368, with a fragment mass of m/z 350 (loss of water molecule). Since E. 
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elatior is rich in chlorogenic acid, it is possible that this peak may be from 
chlorogenic acid derivatives; hence, it was assigned as feruloyl quinate (249). 
Peak 8 showed a mass [M-H] of m/z 505 and secondary ions of m/z 269. 
Tertiary ions at m/z 268, 226 and 182 were observed. Based on its mass, a 
tentative assignment of peak 8 was given as feruloyl malate (4-O-8 coupled) 
coniferyl alcohol. The mass spectral data is shown in Appendix 2. 
5.3.7 Identification of compounds in fraction 12 by LC-MS
n
 
HPLC chromatograms (in 2-D and 3-D) of fraction 10 are shown in 
Figure 28. Identification of the peaks obtained by LC-MS is summarized in 
Table 6. Peak 9 showed a [M+H] ion at m/z 280, and MS
2
 ions at m/z 244 and 
216 (loss of 2 water molecules) which could tentatively be identified as 
coumaroyl aspartate (250). Peaks 10 and 12 were identified as 1, 7 bis(4-
hydroxyphenyl)-2, 4, 6 hetatrienone [M+H] ion at m/z 294 and MS2 fragment 
at 276. This compound has been previously isolated and characterized from E. 
elatior (239). Peak 11 showed a mass [M+H] at m/z 268 and a MS
2
 fragment 
at m/z 135, with a loss of m/z 133, which is characteristic of the compound 
genistein (251). Stigmast-4-en-6β-ol-3-one and 5α, 8α–epidioxyergosta-6, 22-
dien-3β-ol both possess a molecular weight of 428 g/mol, have previously 
been isolated in the ginger flower, and can possibly be identified in peak 13 
(239). Peak 14 can be identified as dicaffeoylquinic acid, which, according to 
the diagnostic fragmentation pattern, involves cleavage of the caffeoyl and 
quinic (m/z 190) moieties (252). Our spectral data showed a mass of [M–H]- 
ion at m/z 707 and secondary and tertiary peaks at m/z 353 and 190 
respectively (253). Peak 15 was identified as β-stigmasterol with a [M+H] ion 
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at m/z 415 and MS
2
 fragment at 406 which was previously identified in E. 
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(mins) 
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(nm) 


















         
2 25.3 279 578 579 [M]
+
 427, 291 270 Procyanidin B1 Venter, 2013 
         
3 30.3 - 290 291 [M]
+
 273, 122 - Epi(catechin) - 
         
4 34.8 - 626 465 [M]
+
 465, 303 303 
Quercetin-3,4'-O-di-β-
glucopyranoside 
Shui and Leong, 
2004 
         
5 71 - 354 355 [M]
+
 162, 174 144 Monocaffeoylquinic acid Wong,  2007 
         
6 74.4 - 520 519 [M-H]
-
 269, 181 268, 226, 164 
Diconiferyl alcohol glucoside/ 
alaschanioside C 
Saracoglu 2003 
         
7 75.1 - 367 368 [M]
+
 350 332 Feruloyl quinate Simirgiotis, 2013 
         
8 78.8 - 506 505 [M-H]
-
 269 268, 226, 182 














































Table 6. Identification of polyphenolic compounds from the aqueous extract (fraction 12) by HPLC-MS
n
. 
Peak no. tR (mins) UVmax 
(nm) 














9 3.3 - 279 280 [M]
+
 262 244, 216 Coumaroyl aspartate 
Pereira-Caro et. al., 
2013 








11 5.9 223, 274 268 268 [M]
+
 135 - Genistein 
Ye et. al., 2012; Kang 
et. al., 2007 








13 7.8 250 428 429 [M]
+














353 190 Dicaffeoylquinic acid 











This study indicates that the potent α-amylase inhibition of E. elatior 
extract was largely attributed to the presence of PACs. However, it is likely 
that there may be other inhibitors present that may have added to the 
inhibitory activity of α-amylase, especially in the aqueous fraction.  However, 
there are more compounds within the fractions that have not been adequately 
separated on the column, and hence could not be characterised. It is possible 
that these unseparated compounds may have contributed to the observed 
inhibition of α-amylase. Hence, the present data warrants further in-depth 






Synergism of epigallocatechin gallate towards 
dracoflavan B and acarbose on the inhibition of 
α-amylase   
6.1 Introduction 
There is much research currently done that screens for anti-diabetic 
drugs in plants that contain polyphenolic secondary metabolites (254). 
Nonetheless, many of these polyphenolic compounds have poor serum 
bioavailability (255) and are unable to enter the circulatory system to 
influence cellular interactions; consequently, a viable and promising strategy 
of controlling this disease is via the gastrointestinal tract, since a large portion 
of ingested polyphenolic compounds remains there and proceeds to the large 
intestine for microbiota biotransformation (256). Hence, this suggests that part 
of the health benefits derived from polyphenol-rich diets stem from its 
bioactivity within the gastrointestinal tract. Current conventional drugs, like 
acarbose, work through the gastrointestinal tract by inhibiting starch 
hydrolases like α-amylase and α-glucosidase. Starch digestion is retarded by 
inhibiting these enzymes, thus slowing down glucose absorption, which leads 
to a decrease in PPHG (5). These strong inhibitors are effective, but cause 
undesirable side-effects like flatulence and diarrhoea (257). In view of this, we 
propose drug combination as a plausible means of reducing these undesirable 
side-effects, by decreasing the dosage of the active inhibitors while 
maintaining its efficacy for glycaemic control. In addition, much work has 
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been done on individual inhibitors, but not on exploring the potential of 
synergism between drug combinations. TCM has utilised combination 
therapies for more than 2500 years to treat diseases, and TCM practitioners 
believe that synergistic interactions between the components of a single plant 
or a mixture of medicinal plants play a vital role for their therapeutic efficacy 
(258, 259).  
In line with this, there have been several studies which look into the 
action of synergism, by combining commonly found flavonoids in foods with 
acarbose. For example, a combination of cyanidin-3-glucoside, cyanidin-3-
galactoside and cyanidin-3,5-diglucoside with low concentrations of acarbose 
were shown to produce synergistic inhibition of maltase and sucrose (260). In 
addition, green tea extracts, green tea polyphenols or EGCG, when combined 
with acarbose, produced synergistic effects to inhibit α-amylase and α-
glucosidase at low concentrations (261). Polyphenol-rich extracts from 
blackcurrant and rowanberries were also shown to potentiate the inhibition 
caused by acarbose. Their results showed that blackcurrant and rowanberry 
extracts inhibited α-glucosidase with an IC50 of 20 and 30 µg GAE/mL 
respectively, which is lower than the IC50 of acarbose (~ 40 µg/mL). The 
combination of acarbose at its IC50 value, and berry extracts at their IC50 
values, caused increased inhibition (262). The additive effect between 
acarbose and cinnamon extract was also noted (263). Dried plant extracts of 
Hibiscus sabdariffa (Roselle), Chrysanthemum indicum (Chrysanthemum), 
Morus alba (Mulberry), Aegle marmelos (bael), and Clitoria ternatea 
(Butterfly pea) were combined with mulberry extract, and the results showed 
an additive interaction with intestinal maltase inhibition. In addition, 
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chrysanthemum, mulberry and bael extracts, together with roselle extract, 
produced synergistic inhibition against α-amylase. It was noted, however, that 
the author applied the glucose-oxidase/peroxidase method to quantify AGH 
inhibition, which is prone to interference by many phenolic compounds. 
Interference could lead to false positives, hence, it is unclear as to whether the 
synergistic/additive effects produced are due to false positives or actual 
inhibition (264).  
Many epidemiological studies have investigated the roles of green tea 
consumption and its benefits to human health, such as prevention of cancers 
and cardiovascular diseases, improvement of the immune system, fighting 
obesity and diabetes (265). Epigallocatechin gallate (EGCG) is one of the 
main polyphenolic components in green tea, and it has also been linked to 
disease prevention. In addition, another component includes dracoflavan B 
(DFB), a compound isolated from „dragon‟s blood‟, a common name used for 
the resins and saps of four types of plant genera: Croton (Euphorbiaceae), 
Dracaena (Dracaenaceae), Daemonorops (Palmaceae) and Pterocarpus 
(Fabaceae) (266). The resin from „dragon‟s blood‟ is collected from 
Daemonorops draco in Southeast Asian countries. DFB, a highly selective 
inhibitor of α-amylase, does not show activity against α-glucosidase 
(unpublished data).  This work hypothesizes that the application of a more 
highly selective inhibitor against α-amylase would result in fewer side effects. 
Two different inhibitory compounds were applied: DFB and acarbose, in 
combination with EGCG, to assess the synergistic effects on enzyme 




Figure 29. The combination of EGCG with DFB and acarbose for synergism in α-
amylase inhibition activity. 
 
Docking studies were applied in order to better understand the 
mechanism of synergy. Quantification of synergistic effects was done using 
the combination index (CI), which compares the doses of inhibitors, 
independently and in combinations, that produce the same level of inhibition 
experimentally (267).  
6.2 Materials and methods 
6.2.1 Reagents and instruments 
α-amylase (A3176, type VI-B, from porcine pancreas), corn starch 
(S4126), acarbose (A8980) and epigallocatechin gallate (E4143) were 
obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). 
Dracoflavan B was isolated from the resin from Daemonorops draco. 
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6.2.2 Determination of inhibition using turbidity method 
The turbidity method was described in detail in section 5.2.5. 
6.2.3 Experimental design of inhibitor combinations 
DFB/EGCG: A fixed concentration of DFB (74 µM) was combined 
with various concentrations of EGCG (22, 44, 87, 349 µM). Acarbose/EGCG:  
A fixed concentration of acarbose (7.7 µM) was combined with various 
concentrations of EGCG (34, 136, 273, 545 µM). Each combination series was 
serially diluted by 1.5 times to give a dose-response curve.  
6.2.4 Combination index and median effect equation (268, 269)           
The combination index (CI) was calculated using Equation 12, where 
(D)1 and (D)2 are doses of DFB and EGCG in the combination system 
respectively. (Dx)1 and (Dx)2 are doses of DFB and EGCG alone. (Dx)1 and 
(Dx)2 values were calculated using the median effect outlined in Equation 13, 
whereby the fundamental rule governing this equation is the mass-action law. 
                     )  
  ) 
   ) 
  
  ) 
   ) 
  (Equation 12) 
    (
  
  
)                                (Equation 13) 
 
where   )  = Fraction affected by D,   ) = Fraction unaffected (i.e.   )  = 1- 
  ) ),    = Dose or concentration of drug,    = Median effect dose (i.e.     ), 
  = Coefficient signifying the shape of the dose-effect relationship.  CI < 1, 
CI = 1, and CI > 1 represents synergism, additive and antagonistic effect.  
129 
 
6.2.5 Statistical analysis 
Statistical analysis was performed using SPSS software. The IC50 and 
CI values are given as means ± standard deviations (SDs). Significant 
differences between means were analysed using one-way ANOVA at the p < 
0.05 level.  
6.2.6 Molecular docking studies 
The holo (Protein data bank identification: 1OSE) structure of α-
amylase containing the inhibitor acarbose was obtained from the Protein Data 
Bank. The structures were first prepared via the Protein Preparation Wizard in 
Maestro, where 1) proper bond orders were added, 2) hydrogen atoms that 
were not present in the crystal structure were added, and 3) residues that had 
missing side chains were filled in using Prime. All water molecules that were 
5 Å away from the inhibitor were removed. The protonation states of the 
residues were assigned using PROPKA at the physiological pH of 7.4. The 
dracoflavan B and epicatechin gallate were also prepared in Maestro. The 
docking was run from the graphical user interface accessible within Maestro. 
The top 5 poses for each ligand were retained and scored with the Extra 
Precision scoring function. The respective poses for the primary active site, 
secondary site 1 (SS1) and 2 (SS2), that had the lowest score, were exported 
for molecular dynamics (MD) simulations. 
TIP3-P water molecules were added in an octahedron box with a 
distance of 20 Å. Counterions were added to maintain a neutral environment 
in the system. Minimisation was conducted via a two-step approach. With the 
proteins restrained, the solvent was first minimised for 5,000 steps via the 
steepest descent method, and an additional 5,000 steps via the conjugate 
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gradient method. The protein-solvent system was then minimised till the 




. The system was then heated 
from 0 to 300 K for 100 ps. Equilibration was done at a constant temperature 
of 300 K, with a time step of 2.0 fs for 5 ns. Snapshots were taken every 1 ps 
during the simulation to generate the coordinate trajectory file. Temperature 
regulation was done using Langevin dynamics, with the collision frequency 
set to 4 ps
-1
. The heat bath coupling of the system was set to 2 ps and the 
simulations were done with isotropic position scaling. Equilibration was done 
at a constant pressure of 1 bar with a pressure relaxation time of 2 ps. All the 
bonds involving hydrogen were constrained using SHAKE. The distance 
cutoff for non-bonded interactions was set to 12 Å.  
Three trajectories with different seed numbers were run for each 
protein-ligand complex. The binding free energies were then calculated with 
Sietraj and averaged between the three trajectories. Visualization of the 
protein-ligand complexes was done with the Visual Molecular Dynamics 
software. 
6.3 Results and discussion 
6.3.1 Inhibition of the various combinations of DFB and EGCG  
Figure 30 (upper left) shows the dose-response curves of the 
maximum fixed concentration of DFB at 74 µM, spiked with EGCG at 
concentrations 22, 44, 87 and 349 µM, and each DFB and/or EGCG 
combination was serially diluted step-wise by a factor of 1.5. Our results show 
that as the concentration of EGCG increases, the slope of the dose-response 
curve becomes steeper, thus resulting in a smaller IC50 value. The same trend 
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was seen with acarbose and EGCG (Figure 30, upper right).  Acarbose was 
fixed at a concentration of 7.7 µM and spiked with EGCG at concentrations 
34, 136, 273 and 545 µM. Using the dose-response curve generated, the IC50 
of the combinations of DFB/EGCG and acarbose/EGCG were calculated and 
shown in Figure 30 (below). On its own, DFB gave an IC50 of 100 ± 7 µM, 
whereas EGCG alone gave a very high IC50 value of 539 ± 93 µM. With the 
DFB concentration fixed at 74 µM, the addition of EGCG at 22 and 44 µM 
would give an IC50 of 90 ± 2 and 83 ± 5 µM respectively, which is 
significantly different (p < 0.05) from DFB alone, but not significantly 
different (p > 0.05) among the EGCG cases themselves. Nevertheless, the 
subsequent increase in the concentration of EGCG, to 87 and 349 µM, 
significantly decreases (p < 0.05) the IC50, to 71 ± 4 and 60 ± 4 µM 
respectively, compared to the IC50 of just DFB alone. 
On its own, acarbose gave an IC50 value of 5.9 ± 2.3 µM. With the 
concentration of acarbose fixed, the addition of EGCG at a concentration of 34 
µM lowered the IC50 slightly, although not significantly (p > 0.05), to 5.1 ± 
1.9 µM. A subsequent increase in the concentration of EGCG to 136 µM 
decreased the IC50  to 3.7 ± 0.6 µM. Further additions, of 273 and 545 µM of 
EGCG, resulted in a significant decrease (p < 0.05) in IC50,  of 2.5 ± 0.2 and 




Figure 30. Dose-response curves of the % of inhibition of α-amylase by DFB spiked 
with different concentrations of EGCG (upper left), dose-response curves of the % of 
inhibition of α-amylase by acarbose spiked with different concentrations of EGCG 
(upper right), IC50 values of fixed DFB and acarbose combined with various 
concentrations of EGCG (below). 





7.7 µM acarbose, 
Ø
 2.3 µM acarbose, 
ǂ 
700 µM EGCG.  Significant 
difference between means were analysed using one-way ANOVA (Duncan test), 
where different alphabets represent significant differences at the p < 0.05 level. 
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6.3.2 Combination index plot of DFB/EGCG and acarbose/EGCG 
In order to discern if the increase in the concentration of EGCG within 
media produced an additive or synergistic effect, we used the Combination 
Index (CI), which is a method of quantifying addition, synergism or 
antagonism between two drugs. The concept and equation (Equation 12) was 
introduced by Chou and Talalay (270). CI values will indicate synergism (<1), 
additive (=1) or antagonistic (>1) effects respectively. Figure 31 (left) shows 
the CI plot with all four combination ratios of a fixed concentration of DFB at 
74 µM, spiked with 22, 44, 87 and 349 µM of EGCG. All the DFB/EGCG 
combinations gave CI values lesser than 1, which indicates synergistic 
interactions. In addition, our results also show that the strength of synergism is 
dependent on the concentration of EGCG within the system, and all the 
different concentrations tested gave a CI value that were significantly different 
(p < 0.05) from each other. Based on the classification developed by Chou 
(1991) (267), the addition of EGCG at 22 and 44 µM gave a CI value of 0.8 ± 
0.05 and 0.7 ± 0.08 respectively, classifying it in the „moderate synergism‟ 
category. A further addition of 87 and 349 µM of EGCG brings the system to 
the „synergism‟ category, with a decrease in CI value to 0.63 ± 0.1 and 0.5 ± 
0.07, respectively.  
Similarly, Figure 31 (right) shows the CI plot with four combinations 
of acarbose and EGCG, with acarbose fixed at 7.7 µM and EGCG at 
concentrations 34, 136, 273 and 545 µM. All the different combinations gave 
CI values lesser than 1, which indicates synergistic interactions. Addition of 34 
µM EGCG to acarbose gave an average CI value of 0.77 ± 0.08, which is in the 
„moderate synergism‟ category. A further addition of 136 and 273 µM EGCG 
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into the system brings it to the „synergism‟ category, with a CI value of 0.6 ± 
0.04 and 0.41 ± 0.05 µM respectively. Finally, EGCG, at a concentration of 
545 µM, gave the lowest CI value of 0.3 ± 0.06, under the „strong synergism‟ 
category.  
Our results indicate that EGCG works synergistically with DFB and 
acarbose to inhibit α-amylase. In addition, the extent of synergism is related 
to the amount of EGCG in the combination system; that is, the higher the 
concentration of EGCG in combination with acarbose and DFB, the stronger 
the synergistic effect. 
6.3.3 Docking studies 
Previous kinetic analysis revealed that DFB binds non-competitively 
to α-amylase (i.e. binding to a location on the enzyme that is different from 
the active site) with starch as the substrate, with a Ki value of 11.7 µM 
(results not published). Our results also seem to support the notion that EGCG 
may bind non-competitively to the enzyme, since the addition of a relatively 
high concentration of EGCG (700 µM) to the assay did not seem to affect the 
catalytic activity of the amylase to digest starch. In line with our findings, 
previous studies showed that EGCG binds non-competitively to human 
salivary α-amylase, with a calculated Ki value of 0.46 mM. 
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Figure 31. Combination index plot of DFB-EGCG of the dose-response curve 
(upper left), combination index plot of acarbose-EGCG of the dose-response curve 
(upper right), combination index values and CI category of DFB and acarbose at 
different concentrations of EGCG (below). 
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In addition, EGCG was able to dock without affecting the binding to 
the catalytic sites of α-amylase. It was suggested that there are two types of 
docking machineries of EGCG on salivary α-amylase: the first is due to the 
hydrogen bonds between the hydroxyl groups of polyphenols and the amino 
acid residues, the other due to aromatic interactions of benzene rings between 
polyphenols and tryptophan residues of α-amylase (75). In light of this, EGCG 
was proposed to be able to dock at one or both of the secondary binding sites 
(SBSs). 
Even though previous studies used human pancreatic -amylase, the 
amino acid sequences for mammalian α-amylases have been shown to be 
similar in homology (69). In addition, the crystalline structure of α-amylases 
from human pancreases and saliva was shown to be similar to that of PPA. The 
comparisons revealed that the catalytic residues are not only similar, but most 
of the residues forming the substrate-binding site also have similar orientation 
(271). Hence, this assumes that the binding of EGCG to human pancreatic -
amylase and for PPA would be very similar.   
In our DFB/EGCG system, both inhibitors are hypothetically non-
competitive in nature, which raises the question of whether two non-
competitive inhibitors, when applied together, can cause synergism to occur. In 
the simplest molecular case, if two non-competitive inhibitors target the same 
site on the enzyme, mutually exclusive binding would result, where, if one 
inhibitor is present, the addition of the second would only produce an additive 
effect. However, in our case, since two secondary binding sites exist on α-
amylase (SBS1 and SBS2), it is possible that two inhibitors may bind 
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simultaneously, resulting in a case of “mutually non-exclusive” binding (272). 
Here, the two inhibitors would have specific and independent sites on the 
enzyme where the binding of one inhibitor would not prevent the binding of 
another to the enzyme, thus generating additional inhibited states of the 
enzyme (Figure 32).  
 
Figure 32. A schematic representation for two mutually non-exclusive, non-
competitive inhibitors. 
 
In order to gain a better understanding of its mechanism of inhibition, 
we applied molecular docking studies of the two ligands and the two 
secondary binding sites of α-amylase. Interestingly, MD simulations showed 
that both EGCG and DFB bind to the secondary binding sites of α-amylase, 
with one inhibitor having a preference towards one binding site over the other 
(Table 7).  
 
Table 7. Binding site energies of EGCG and DFB at secondary binding sites 1 and 2. 






SS1 -11.25 -7.98 
SS2 -4.83 -5.88 
Protocol 2: 
GB 
SS1 -8.11 -5.78 
SS2 -7.41 -10.10 
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Larger negative values suggest stronger binding energy between the 
enzyme and the ligand. Binding energy of EGCG to SBS1 was -11.25 
kcal/mol, whereas DFB had a lower binding energy of -7.98 kcal/mol to 
SBS1. However, for SBS2, DFB revealed a larger binding energy of -5.88 
kcal/mol as compared to the binding energy of EGCG, which was -4.83 
kcal/mol.  A similar trend was observed when a different protocol (protocol 2: 
GB) for energy calculations was used. The binding energies of EGCG and 
DFB at SBS1 were -8.11 kcal/mol and -5.78 kcal/mol respectively. For SBS2, 
DFB showed a higher binding energy compared to EGCG, which was -10.10 
kcal/mol versus -7.41 kcal/mol respectively. Hence, EGCG was shown to have 
a preference of binding to SBS1, and DFB to SBS2. This explains the 
synergistic activity of EGCG and DFB towards the inhibition of α-amylase 
activity. We propose that there was „Bliss Independence‟ occurring, where 
mutually non-exclusive binding results in cooperative inhibition of α-amylase. 
Since the two inhibitors each have a preference for an independent site, the 
inhibitors are able to bind, simultaneously and being mutually non-exclusive, 
through distinct mechanisms, without having to compete with one another for 
a specific binding site, thus resulting in synergistic inhibition against α-
amylase. Since EGCG has relatively weak activity against α-amylase, it can be 
said that EGCG augments or potentiates the activity of DFB. It is possible that 
the binding of EGCG to α-amylase induces a conformational change that 
opens up the binding site for DFB for it to bind more strongly.  
In the case of the acarbose/EGCG system, acarbose is a competitive 
inhibitor of α-amylase (273). Hence, this explains the synergistic activity of 
acarbose and EGCG against α-amylase, as a combination of both competitive 
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and non-competitive modes, which arise through binding at the active site, as 
well as a secondary site on the enzyme, resulting in a superadditive effect. 
Previous studies have also demonstrated that such synergistic activity is 
produced via the action of a competitive and a non-competitive inhibitor. For 
instance, chlorogenic acid (CGAs) and its derivatives (274), and finger millet 
phenolics (275), are shown to be non-competitive inhibitors. Berry 
components rich in CGAs and other phenolics are shown to potentiate the 
inhibition caused by acarbose (262).  
6.3.4 3-D and 2-D interaction plot of EGCG, DFB to the secondary 
binding sites and acarbose to the catalytic site of α-amylase 
Figure 33 shows a 3-D depiction of the three inhibitors binding to 
different sites of α-amylase, based on the binding energies in Table 7. DFB 
binds to SBS2, which is located between the interface of domains A and C of 
the free enzyme structure. EGCG has a binding preference towards SBS1, 
which is located near the catalytic site in domain A where acarbose binds to.  
Figure 34 (a) shows a 2-D interaction plot between DFB and SBS2. 
The hydroxyl group at the 7
th
 position of the A-ring in flavan 1 displays H-
bonding to the side chain of Arg343, and hydrophobic interaction with 
Val383. The methyl group in 6
th
 position of the A-ring in flavan 1 shows 
hydrophobic interaction with Phe315. The methoxy group in the 5
th
 position of 
the A-ring in flavan 1 has hydrophobic interaction with Ala318, negatively 
charged interaction with Glu484, and positively charged interaction with 
Lys322. In addition to hydrophobic interactions, ring B of flavan 1 has a 
multitude of interactions which includes polar interactions with Thr377 and 
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Thr376, positively charged interactions with Arg387 and 389, hydrophobic 
interaction with Trp388, and negatively charged interaction with Asp375.  
 
Figure 33. 3-D structure of PPA with three inhibitors: (a) DFB, (b) Acarbose and (c) 
EGCG at their proposed binding sites. 
 
  
Figure 34 (b) shows the 2-D ligand interaction plot between EGCG 
and α-amylase. There were hydrophobic interactions between the catechin (A-
C ring) moiety with Trp203 and Tyr155. The two hydroxyl groups in the 
gallate moiety (D-ring) were shown to have hydrogen-bonding interactions 
with the side chain of Gln243. In addition, the hydroxyl group in the epigallo 
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(B-ring) moiety at 3' forms hydrogen bonds with the side chain of Glu246. 
The hydroxyl group at 4' forms hydrogen bonds and hydrophobic interactions 
with the backbone of carboxyl oxygen of Ala241.  
In all, hydrogen bonding and hydrophobic interactions play a 
significant role in the binding of EGCG and DFB to the secondary binding 




Figure 34. 2-D interaction plot of (a) DFB and (b) EGCG to their respective binding 















This study shows synergistic activity against α-amylase inhibition 
when EGCG was combined with conventional drugs, like DFB and acarbose. 
The extent of synergy was dependent on the amount of EGCG in the system, 
that is, the higher the concentration of EGCG in the system, the higher the 
potency of the combination towards inhibiting α-amylase (i.e. a lower IC50 
value). Through MD simulation studies, EGCG was shown to have a binding 
preference for SBS1 and DFB to SBS2. The binding of the ligands to the 
binding sites are shown to be mainly through hydrogen bonding and 
hydrophobic interactions. „Bliss independence‟, or mutually non-exclusive 
binding, was proposed to have occurred with the two inhibitors in their 
inhibition of α-amylase, which accounts for the synergistic activity observed.  
This study provides valuable implications for an alternative therapy for type 2 
diabetics, using a combination of inhibitors. Furthermore, it also provides new 
insight into the use of naturally occurring enzyme inhibitors in foods rich in 










Overall conclusions and future study  
The number of type II diabetes cases is on the rise worldwide, and 
much research is focused on finding novel ways of mitigating this problem.  A 
promising source for discovering new bioactive ingredients, which could be 
applied to treat diabetics, is the rich resource of tropical medicinal plants. 
There is a need for more specific inhibitors from natural sources to decrease 
undesirable side-effects like flatulence and diarrhoea that are frequently 
caused by conventional drugs.  This work aims to tackle these two problems 
simultaneously and find potential solutions.  
The first part of this project (Chapters 2 & 3) aims to validate the use 
of in vitro high-throughput colorimetric assays that are typically used to screen 
for starch hydrolase inhibitors. In chapter 2, a comparative study of native and 
artificial substrates was carried by measuring the Ki and Ki' of two known 
inhibitors (acarbose and 1-DNJ). Large differences were found between the Ki 
and Ki
'
 of both inhibitors when different substrates were used. When pNPG 
was applied, the Ki of acarbose (130 ± 10 µM) and 1-DNJ (0.18 ± 0.04 µM) 
were shown to be consistently larger than when maltose was used as the 
substrate (Ki = 0.07 ± 0.01 and 0.01 ± 0.008 µM for acarbose and 1-DNJ, 
respectively).  This chapter concludes that the use of native starch is vital in 
order to get an accurate indication of the interaction and potency of the 
inhibitors with the enzymes. Following this, chapter 3 shows the susceptibility 
of the GOP assay to interference by polyphenolic compounds that are 
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commonly found in botanicals. More specifically, this study found that 
compounds in the “high interference” group possess many OH groups that are 
in the ortho position.  These findings from chapters 2 and 3 caution future 
research to first validate assays used for HTS of starch hydrolase inhibitors 
before their application. Furthermore, in order for the results to be relevant, 
assays should be accurately designed such that they mimic physiological 
reactions as closely as possible. The failure to validate assays before 
application may inadvertently lead to false results and wrong conclusions, 
which may mislead future work and result in a waste of resources.  
The second part of this project involves applying the turbidity assay, 
which uses starch as the substrate, and to screen through a total of 298 
botanicals for starch hydrolase inhibition. Out of the 298 samples tested, 71 
showed activity, and were either edible and/or possessed medicinal value. 
Finally, 12 out of the 71 that showed activity stood out in terms of their starch 
hydrolase inhibition, as well as their historical use as medicinal herbs. A weak 
correlation was found between PAC and TPC contents with starch hydrolase 
inhibition, which indicates that there may be other specific inhibitors that may 
have contributed to its potency. This warrants further in-depth study to 
discover, characterise and isolate novel inhibitors. Although the correlation 
between TPC and starch hydrolase inhibition was low, plant extracts which 
have high TPC have potential for further development as anti-diabetic drugs, 
since these plants work through other mechanisms to control blood sugar 
levels. This research lays the important groundwork of screening for starch 
hydrolase inhibition, which is necessary for future in-depth studies of isolation 
and characterisation of novel compounds. 
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In line with this, a further step was taken and assay-guided 
fractionation and separation of the polyphenolic compounds from the ginger 
flower (Etlingera elatior) was conducted. Results show that proanthocyanidins 
in the flower were one of the main components for its high starch hydrolase 
inhibition.  It is possible that other inhibitors besides PACs are present in the 
aqueous phase. Furthermore, it is also plausible that interactions between 
different groups of compounds can have a concerted action on the enzymes, to 
give synergistic inhibitory activity. Hence, further work could include 
identifying other active compounds within the ginger flower, as well as 
applying the ginger flower into a food system (e.g. bread or noodles) to create 
functional foods that are suitable for diabetics.  
The final part of the project is to explore synergistic effects of tea 
catechins with acarbose (an anti-diabetic drug) and DFB, with the rationale of 
enhancing the effectiveness of conventional drugs through the use of 
commonly consumed foods like tea. Results indicate that acarbose and DFB 
are able to work together synergistically with EGCG to inhibit α-amylase. 
Through molecular docking studies, we suggest that the synergy occurs 
through the „bliss independence‟ mechanism. In addition, this study also found 
that the extent of synergy is dependent on the amount of EGCG in the system - 
that is, the higher the concentration of EGCG in the system, the higher the 
synergy observed.  This opens up a variety of possibilities for identifying 
synergistic reactions. For example, there are many other polyphenolic 
compounds (e.g. quercetin and kaempferol) present in many foods that can be 
studied and applied with conventional drugs. Their various interactions can 
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also be studied via molecular docking research to understand their structural 
activity.  
Much work has been done on looking at individual inhibitors, but not 
on exploring the potential of synergism between drug combinations. This 
work shows that drug combination, coupled with everyday foods, is a 
plausible means of reducing undesirable side-effects, by decreasing the dosage 
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Table 8. Inhibition activities (IC50) of flavonoids on α-amylase and α-glucosidase by various researchers. 




Kamiyama et.al. (2010) rat intestine 16  GOP 
Tadera et.al.(2006) rat intestine (32 %) GOP (2 % maltose) 
Matsui et. al. (2007) rat intestine 40  GOP/ iAGH assay  
Xu et.al.(2013) rat intestine 914  pNPG 
Gamberucci et.al.(2006) rat liver 47.72  pNPG 
Yilmazer-musa et.al. (2012) yeast (0.02 U/mL) 0.65  pNPG (0.045 mM) 
Li et. al. (2007) yeast (0.2 U/mL) 537.9  pNPG (0.3125 mM) 
Gao et.al.(2013) yeast (1 U/mL) 11.5  pNPG G (1.25 mM) 
Tadera et.al.(2006) yeast (0.01 mg/mL) 2 pNPG (0.147 mM) 
Deng et.al. (2014) yeast (immobilized) 0.67  UHPLC-QTOF MS 





Yilmazer-musa et.al. (2012) Human saliva (0.0025 U/mL) 52.4  
DQ starch substrate from 
enzchek ultra amylase 
assay kit (5 µg/mL) 
Hara (2001) Human saliva 260  colorimetric method 
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Miao et.al.(2014) Human pancreas 2300  Nelson-Somogyi  
Gao et.al.(2013) 
Porcine pancreas (0.125 
mg/mL) 
4033  DNSA (1 % starch) 
Xu et.al.(2013) 






Porcine pancreas (0.03 
mg/mL) 







Kamiyama et.al. (2010) rat intestine 40  GOP 
Matsui et. al. (2007) rat intestine 53  GOP/ iAGH assay  
Yilmazer-musa et.al. (2012) yeast (0.02 U/mL) 7.9  pNPG (0.045 mM) 
Xu et.al.(2013) rat intestine 1487  pNPG 
Deng et.al. (2014) yeast (immobilized) 0.48  UHPLC-QTOF MS 




Gamberucci et.al.(2006) rat liver 19.06  pNPG 
α-amylase 
Yilmazer-musa et.al. (2012) Human saliva (0.0025 U/mL) 61.03  
DQ starch substrate from 
enzchek ultra amylase 
assay kit (5 µg/mL) 
Miao et.al.(2014) Human pancreas 1400  Nelson-Somogyi  
Hara (2001) Human saliva 130  colorimetric method 
Xu et.al.(2013) 










Kamiyama et.al. (2010) rat intestine 67  GOP 
Yilmazer-musa et.al. (2012) yeast (0.02 U/mL) 3.1  pNPG (0.045 mM) 
Xu et.al.(2013) rat intestine 29  pNPG 
Deng et.al. (2014) immobilized yeast AGH 0.59  UHPLC-QTOF MS 




Gamberucci et.al.(2006) Glucosidase II from rat liver 3.7  pNPG 
α-amylase 
Yilmazer-musa et.al. (2012) Human saliva (0.0025 U/mL) 37.1  
DQ starch substrate from 
enzchek ultra amylase 
assay kit (5 µg/mL) 
Miao et.al.(2014) Human pancreas 1100  Nelson-Somogyi  
Hara (2001) Human saliva 55  colorimetric method 
Xu et.al.(2013) 








Kamiyama et.al. (2010) rat intestine 62  GOP 
α-amylase 




Kamiyama et.al. (2010) rat intestine 120  GOP 
Matsui et. al. (2007) rat intestine 1260  GOP/ iAGH assay  
Yilmazer-musa et.al. (2012) yeast (0.02 U/mL) ND pNPG (0.045 mM) 
Xu et.al.(2013) rat intestine ND pNPG 
Deng et.al. (2014) immobilized yeast AGH 560  UHPLC-QTOF MS 
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Tadera et.al.(2006) yeast (0.01 mg/mL) 75  pNPG (0.147 mM) 
Tadera et.al.(2006) rat intestine (7 %) GOP 




Gamberucci et.al.(2006) Glucosidase II from rat liver 110.7  pNPG 
α-amylase 
Yilmazer-musa et.al. (2012) Human saliva (0.0025 U/mL) ND 
DQ starch substrate from 
enzchek ultra amylase 
assay kit (5 µg/mL) 
Miao et.al.(2014) Human pancreas 38200  Nelson-Somogyi  
Hara (2001) Human saliva >1000  colorimetric method 
Xu et.al.(2013) 





Tadera et.al.(2006) Porcine pancreas > 500  BPNPG7 
(-)-Epicatechin (EC) α-glucosidase 
Kamiyama et.al. (2010) rat intestine 290  GOP 
Matsui et. al. (2007) rat intestine 770  GOP/ iAGH assay  
Yilmazer-musa et.al. (2012) yeast (0.02 U/mL) >1000  pNPG (0.045 mM) 
Xu et.al.(2013) rat intestine ND pNPG 
Deng et.al. (2014) immobilized yeast AGH 526  UHPLC-QTOF MS 
Tadera et.al.(2006) yeast (0.01 mg/mL) >200  pNPG (0.147 mM) 
Tadera et.al.(2006) rat intestine (5 %) GOP 
α-amylase 
Yilmazer-musa et.al. (2012) Human saliva (0.0025 U/mL) ND 
DQ starch substrate from 




Miao et.al.(2014) Human pancreas 40500  
Nelson-Somogyi 
 
Hara (2001) Human saliva >1000  colorimetric method 
Xu et.al.(2013) 





Tadera et.al.(2006) Porcine pancreas > 500  BPNPG7 
Gallocatechin (GC) α-glucosidase 
Kamiyama et.al. (2010) rat intestine 320  GOP 
Xu et.al.(2013) rat intestine ND pNPG 




Gamberucci et.al.(2006) Glucosidase II from rat liver 102.7  pNPG 
α-amylase 
Hara (2001) Human saliva >1000  colorimetric method 
Xu et.al.(2013) 





Catechin (C) α-glucosidase 
Yilmazer-musa et.al. (2012) yeast (0.02 U/mL) 107 pNPG (0.045 mM) 
Xu et.al.(2013) rat intestine ND pNPG 
Tadera et.al.(2006) yeast (0.01 mg/mL) >200  pNPG (0.147 mM) 
Tadera et.al.(2006) rat intestine (1 %) GOP 
Oki et.al.(1999) yeast α-glucosidase 130  pNPG 
Oki et.al.(1999) rat intestine 2700  Maltose 
α-amylase 
Yilmazer-musa et.al. (2012) Human saliva (0.0025 U/mL) 551 
DQ starch substrate from 
enzchek ultra amylase 
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assay kit (5 µg/mL) 
Miao et.al.(2014) Human pancreas 45900  Nelson-Somogyi 
Hara (2001) Human saliva >1000  colorimetric method 
Xu et.al.(2013) 





Tadera et.al.(2006) Porcine pancreas > 500 BPNPG7 
Theaflavins α-glucosidase 
Matsui et. al. (2007) rat intestine 500  GOP/ iAGH assay 
Hara (2001) Human saliva 18  colorimetric method 
Theaflavin-3-O-gallate Matsui et. al. (2007) rat intestine 10  GOP/ iAGH assay 
Hara (2001) Human saliva 1.0  colorimetric method 
Theaflavin-3’O-gallate Matsui et. al. (2007) Rat intestine 136  GOP/ iAGH assay 
Hara (2001) Human saliva 1.7  colorimetric method 
Theaflavin-3,3’-di-O-
gallate 
Matsui et. al. (2007) Rat intestine 58  GOP/ iAGH assay 
Hara (2001) Human saliva 0.6 colorimetric method 
Theasinensin A Matsui et. al. (2007) rat intestine 142  GOP/ iAGH assay 
Acarbose α-glucosidase 
Matsui et. al. (2007) rat intestine 0.43  GOP/ iAGH assay 
Ani & Naidu (2008) rat intestine 0.0003 GOP (6 mM) 
Ani & Naidu (2008) rat intestine 0.18 pNPG (0.35 mM) 
Oki et.al. (1999) rat intestine (0.032 U/mL) 63  pNPG (1.2 mM) 
Kim et. al. (2010) 
Bacterial (B. 
stearothermopillus) (0.025  
U/mL) 
3.25 pNPG (0.3 mM) 
Yilmazer-musa et.al. (2012) yeast (0.02 U/mL) 141  pNPG (0.045 mM) 
Li et. al. (2007) yeast (0.2 U/mL) 242  pNPG (0.3125 mM) 
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Wu et. al. (2013) yeast (0.6 U/mL) 217 pNPG (7.8 mM) 
Takahashi & Miyazawa (2012) yeast (0.02 U/mL) 907.5  pNPG (0.25 mM) 
Choi et. al. (2010) yeast (0.32 U/mL) 9110 pNPG (2.3 mM) 
Oki et.al. (1999) pig intestine 87 pNPG (1.2 mM) 
Oki et.al. (1999) rabbit intestine 62 pNPG (1.2 mM) 
α-amylase 
Piparo et.al.(2008) Human saliva (0.18 µM) 0.996 
Nelson-Somogyi (0.15 
µg) 
Yilmazer-musa et.al. (2012) Human saliva (0.0025 U/mL) 10.7 
DQ starch substrate from 
enzchek ultra amylase 
assay kit (5 µg/mL) 
Grussu et. al. (2011) 
Porcine pancreas (0.38 
mg/mL) 
1.24  DNSA (0.3 %) 
 Sudha et. al. (2011) Porcine pancreas (0.01 U/mL) 15.8 DNSA (0.25 %) 
 
Funke & Melzig (2005) Porcine pancreas (25 U/mL) 23 
p-Nitrophenyl-α-d-
maltopentaoside 
(PNPG5) (18.75 mM) 
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Figure 40. Mass spectra from LC-MS analysis of peak 6 of fraction 10 (diconiferyl 
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Figure 42. Mass spectra from LC-MS analysis of peak 8 of fraction 10 (possibly 
feruloyl malate (4-O-8 coupled) coniferyl alcohol). 
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Figure 47. Mass spectra from LC-MS analysis of peak 15 of fraction 12 (β-
stigmasterol). 
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